TW201822811A - Method for preventing and treating lipid-induced renal injury - Google Patents

Abstract

Provided is a method for preventing and/or treating lipid-induced renal injury and related diseases thereof of a subject, comprising administering a preventively and/or therapeutically effective amount of plasminogen to a subject prone to suffer or suffering lipid metabolism disorders, or suffering other diseases accompanied by lipid metabolism disorders. The present invention also relates to a medicine, pharmaceutical composition, product, and kit comprising plasminogen and used for preventing and/or treating lipid-induced renal injury and related diseases thereof of a subject.

Description

   Method for preventing and treating lipid kidney injury   

The present invention relates to a method for preventing and / or treating fat metabolism disorders and related disorders, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from fat metabolism disorders and related disorders, in order to reduce fat loss. Abnormal deposition of body tissues and organs, so as to achieve the purpose of preventing and / or treating disorders of fat metabolism and related disorders and complications.

Disorders of fat metabolism, also known as fat metabolism disorders, is a type of metabolic disease. It is caused by primary or acquired factors that cause abnormalities in lipids (lipids) and their metabolic products and amounts in blood and other tissues and organs. Metabolism of lipids includes the digestion and absorption of lipids in the small intestine, entry into the blood circulation (via lipoprotein transport) from the lymphatic system, transformation by the liver, storage in adipose tissue, and tissue utilization when needed. The main function of lipids in the body is oxidative energy supply. Adipose tissue is the energy storehouse of the body. Fat can also cooperate with the skin, bones, and muscles to protect the internal organs, prevent body temperature emission, and help the absorption of fat-soluble vitamins in food. Phospholipids are an important structural component of all cell membranes, and cholesterol is a precursor of bile acids and steroid hormones (adrenocortical hormones and gonadal hormones). Lipid metabolism is regulated by heredity, neurohumoral, hormones, enzymes, and tissues and organs such as the liver. When these factors are abnormal, it can cause lipid metabolism disorders and pathophysiological changes of related organs, such as hyperlipoproteinemia and its clinical symptoms, obesity, fatty liver and so on.

Hyperlipoproteinemia is caused by high levels of lipoproteins in the blood. Lipids in the blood such as triglyceride (TG), free cholesterol (FC), cholesterol lipid (CE), and phospholipids are rarely soluble in water, and only form a macromolecular complex (lipoprotein) with apolipoprotein (APO). In order to dissolve, function and metabolize in the blood. Hyperlipemia occurs when blood lipids are above the upper limit of normal people. Because blood lipids are transported in the blood as lipoproteins, hyperlipidemia is also known as hyperlipoproteinemia. Generally, adult fasting blood triglycerides exceeds 160 mg / dl, cholesterol exceeds 260 mg / dl, and children's cholesterol exceeds 160 mg / dl. ^[1]

Hyperlipoproteinemia (hyperlipidemia) is one of the important causes of atherosclerotic lesions, which is a manifestation of abnormal lipid metabolism in the body. Because the types of blood lipids or lipoproteins are different, the types of blood lipids or lipoproteins that are outside the normal range can also be different, so the World Health Organization (WHO) classifies hyperlipoproteinemia into five types: type I, mainly increased chylomicrons, and serum Cloudiness is milky white, which contains a large amount of triglycerides (TG); type II, which is divided into two types: type IIa and type IIb. The former is mainly a low-density lipoprotein (LDL), and the latter is also very low-density lipoprotein (VLDL) Increased; Type III, serum often cloudy LDL and VLDL both increased, and the two were fused on electrophoresis; Type IV, mainly increased VLDL, serum may be cloudy; Type V, chylomicrons and VLDL were increased, serum turbidity was milky white. Among them, type II and type IV are the most common ^[1] .

Hyperlipidemia can be divided into two major categories according to the etiology. Primary causes are mostly caused by congenital defects (or hereditary defects) in lipid and lipoprotein metabolism and certain environmental factors (including diet, nutrition, and drugs) through unknown mechanisms. Secondary is mainly secondary to a certain disease, such as diabetes, liver disease, kidney disease, thyroid disease, as well as drinking and obesity. Environmental factors such as diet and lifestyle are also the cause of the disease.

Diabetes is often associated with disorders of lipid metabolism, so diabetes is also known as "glycolipid disease" ^[2] . The pathogenesis of diabetes is related to B cell function impairment and insulin resistance, which is manifested as chronic hyperglycemia, and disorders of glucose metabolism are often combined with disorders of lipid metabolism. Dyslipidemia of diabetes has become an independent risk factor for cardiovascular disease, which is mainly manifested by hypertriglyceridemia, low-level HDL, and increased LDL concentration.

The mechanism of diabetic lipid metabolism disorder is unclear, but a lot of evidence shows that insulin resistance is the central link of its occurrence. Recent studies have also found that intestinal insulin resistance is also involved. Studies in animal models and populations of diabetes have found that abnormal gene expression related to lipid metabolism further leads to insulin resistance. The occurrence of atherosclerosis in diabetic patients is related to many factors, but abnormal plasma lipid level is the most important factor. Studies have shown that the incidence and mortality of cardiovascular disease in patients with diabetes are significantly higher than those in non-diabetics, and diabetes has become an independent risk factor for cardiovascular disease ^[3] .

In recent years, the relationship between kidney disease and lipid metabolism disorders has become more and more noticeable. Lipid metabolism abnormalities are often accompanied by chronic progressive kidney injury, and hyperlipidemia can promote and aggravate kidney damage, in addition to mediating glomerular injury. In addition, it also plays a role in tubulointerstitial injury. In 1913, Munk first described dyslipidemia in renal syndromes. Some scholars have reported that 70% -10% of patients with renal syndrome can develop hyperlipidemia. It is mainly manifested by a significant increase in total blood cholesterol (TC), and mainly by an increase in low-density lipoprotein cholesterol, and a slight increase in triglycerides (TG). The increase in low-density lipoprotein (LDL) and urine protein There is a certain correlation ^[4] . Patients with chronic renal insufficiency are predominantly of moderate triglycerideemia, the level of total plasma cholesterol is generally normal, and cholesterol in VLDLC and medium-density lipoprotein cholesterol (IDLC) increases. High-density lipoprotein cholesterol (HDLC) decreases, and triglyceride content in various lipoproteins increases. The root cause is the adverse effect of the uremia environment on the synthesis and catabolism of triglycerides and the inhibitory effect on the reverse transport of cholesterol ^[5] .

With the general promotion of kidney transplantation therapy and the widespread application of various new immunosuppressive agents (especially CsA, prednisone), the survival of patients with chronic renal failure (CRF) has significantly prolonged. The incidence is very high. Hyperlipidemia after renal transplantation is mainly manifested in increased levels of plasma total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDLC), and very low density lipoprotein cholesterol (VLDLC) ^[6] .

Clinical studies have confirmed that there is a certain correlation between disorders of lipid metabolism and diabetic nephropathy. Diabetes patients have disordered lipid metabolism, and elevated lipids are deposited in the glomerular basement membrane, which stimulates basement membrane cell proliferation and extracellular matrix production. As early as 1936, Kimmelstiel and Wilson found a large amount of lipid deposition in the renal arteries, glomeruli, and tubules of patients with diabetic nephropathy ^[7] . Abnormal lipid metabolism causes glomerular and tubulointerstitial fibrosis is one of the important causes of progressive damage to renal function ^[8] .

Disorders of lipid metabolism can also cause obesity (obesity syndrome). There are two types of obesity: simple and secondary. Simple obesity refers to obesity without obvious endocrine and metabolic diseases. It can be divided into two types of constitutional obesity and acquired obesity. Physical obesity has a family genetic history. The patient has eaten abundantly from an early age, and has an excessive intake. He is obese from an early age, and the fat cells are hypertrophic. Acquired obesity is mostly caused by excessive nutrition and / or reduced physical activity, such as the improvement of people's physical conditions after middle age, adequate recovery and recuperation of the disease, cessation of physical exercise or manual labor after delivery. Fat cells showed hypertrophic changes, no hyperplasia, and better treatment results. Secondary obesity is mainly caused by neuroendocrine diseases. Neuroendocrine has important regulatory effects on metabolism: ① The hypothalamus has a central appetite, and the sequelae of inflammation of the central nervous system, trauma, and tumors can cause abnormal hypothalamus function, make the appetite strong and cause obesity. ②Increase insulin secretion. For example, patients with early non-insulin-dependent diabetes mellitus may inject too much insulin, which leads to hyperinsulinemia; islet B-cell tumors secrete too much insulin, which increases fat synthesis and causes obesity. ③ Hypothyroidism, especially when hypogonadism and thyroid stimulating hormone decrease cause hypogonadism and thyroid hypofunction, obesity can occur. ④ Women who are pregnant or taking oral contraceptives are prone to obesity, which suggests that estrogen can promote fat synthesis. ⑤ Cortisolism is often accompanied by concentric obesity. ⑥ hypothyroidism, due to low metabolic rate, fat accumulation, and mucus edema. Hypogonadism can also be obese, such as obese reproductive incompetence (cerebral obesity, Flolick's syndrome, trauma, encephalitis, pituitary tumor, craniopharyngioma and other injuries to the hypothalamus, manifested as concentric obesity, With diabetes insipidus and sexual retardation).

Disorders of lipid metabolism often lead to fatty liver. Fatty liver refers to the pathological changes of excessive fat accumulation in liver cells caused by various reasons. The liver plays a particularly important role in lipid metabolism. It can synthesize lipoproteins, facilitate lipid transport, and is the main site for fatty acid oxidation and ketone body formation. Normal liver lipid content is not much, about 4%, mainly phospholipids. If the liver fails to transport fat in time, fat accumulates in liver cells and forms fatty liver.

Fatty liver can be an independent disease or can be caused by other reasons, such as obese fatty liver, alcoholic fatty liver, fast-fat fatty liver, malnutrition fatty liver, diabetic fatty liver, drug-induced fatty liver, and so on.

Certain drugs or chemical poisons cause fatty liver by inhibiting protein synthesis, such as tetracycline, adrenocortical hormone, puromycin, cyclohexanamine, turpentine, and arsenic, lead, silver, mercury, etc. Lipid-lowering drugs can also form fatty liver by interfering with lipoprotein metabolism.

One of the dangers of fatty liver is that it promotes the formation of atherosclerosis. One of the causes of atherosclerosis is that patients with fatty liver are often accompanied by hyperlipidemia and increased blood viscosity. The low-density lipoprotein (LDL) Because of its extremely small molecular weight, it is easy to pass through the intima of the arterial blood vessel and settle on the wall of the blood vessel, reducing the elasticity of the artery, narrowing the diameter of the tube, weakening the flexibility, and eventually causing blood circulation disorders. The other harm of fatty liver is to induce or aggravate hypertension and coronary heart disease, which can easily lead to myocardial infarction and sudden death. The third harm of fatty liver is encephalopathy fatty liver syndrome (Reye syndrome). The fourth harm of fatty liver is to cause cirrhosis, liver failure and liver cancer.

Fatty liver is the product of dyslipidemia of the liver, and at the same time it is a pathogenic factor that aggravates liver damage. This is the development of a causal and vicious circle that is mutually interactive. Lipid droplets in hepatocytes increase, making the hepatocytes fatty and swollen, and the nucleus is squeezed away from the center. The metabolism of fat is carried out in mitochondria. The transport of fat to the outside of the cell mainly passes through the smooth endoplasmic reticulum. The accumulation of fat in liver cells further aggravates the burden of mitochondria and endoplasmic reticulum and reduces its function, which affects other nutrients, hormones, Vitamin metabolism. Long-term degeneration of hepatocytes can lead to regenerative disorders and necrosis of hepatocytes, leading to liver fibrosis and cirrhosis. The risk of cirrhosis secondary to hepatocellular carcinoma is higher.

The fifth harm of fatty liver is acute pregnancy fatty liver with high mortality. This disease, also known as obstetric acute yellow liver atrophy, is a rare and complicated prognosis of pregnancy. It usually occurs in the last three months of pregnancy, and the clinical manifestations are often similar to those of acute and severe liver. Acute liver failure, pancreatitis, renal failure, and systemic coagulation abnormalities can cause rapid death.

The sixth harm of fatty liver is to induce or aggravate diabetes. If the blood glucose concentration of obese fatty liver patients exceeds the normal level, although it does not meet the diagnostic criteria for diabetes, it is generally considered to be pre-diabetes. Fatty liver and diabetes often accompany and interact with each other, which makes clinical treatment more difficult.

The study of the present invention found that plasminogen can prevent and / or reduce the abnormal deposition of fat in body tissues and organs, for example, can prevent and reduce the abnormal deposition of lipids in the blood, blood vessel walls, internal organs and tissues between organs, and improve these tissues The function of organs, thus providing a new prevention and treatment plan for fat metabolism disorders and related disorders, and their accompanying diseases or complications.

The present invention relates to the following items: In one aspect, the present invention relates to: Item 1. A method for preventing and / or treating lipid kidney injury and related conditions in a subject, comprising administering to the subject a preventive and / or therapeutically effective amount Plasminogen, wherein the subject is susceptible to a disorder of fat metabolism, suffers from a disorder of fat metabolism, or suffers from other diseases with lipid kidney damage.

Item 2. The method of Item 1, wherein the lipid kidney injury is an endocrine disorder, a glucose metabolism disease, a liver disease, a kidney disease, a cardiovascular disease, an intestinal disease, a thyroid disease, a gallbladder or biliary disease, obesity, alcohol consumption 2. Lipid kidney injury caused by or accompanied by drug treatment.

Item 3. The method of Item 2, wherein the lipid kidney injury is hyperlipidemia, hypertension, diabetes, chronic glomerulonephritis, chronic pyelonephritis, renal syndrome, renal insufficiency, kidney transplantation, uremia, thyroid function Low, obstructive cholecystitis, obstructive cholangitis, drug or hormone therapy-induced or concomitant lipid kidney damage.

Item 4. The method of any one of Items 1-3, wherein the kidney injury is caused by hyperlipidemia.

Item 5. The method of Item 4, wherein the hyperlipidemia is type I, type IIa, type IIb, type III, or type IV hyperlipidemia.

Item 6. The method of Item 4, wherein the hyperlipidemia comprises one or more selected from the group consisting of: hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, and low-density lipoproteinemia disease.

Item 7. The method of any one of Items 1-6, wherein the plasminogen reduces renal fat deposition.

Item 8. The method of any one of Items 1-7, wherein the plasminogen reduces renal fibrosis.

Item 9. The method of item 8, wherein said renal fibrosis is secondary to renal injury.

In another aspect, the invention relates to: Item 10. A method for preventing and / or treating diabetic lipid kidney injury and related conditions in a subject, comprising administering to the subject a prophylactic and / or therapeutically effective amount of plasminogen .

In another aspect, the present invention relates to: Item 11. A method for preventing and / or treating hyperlipidemia lipid kidney injury and related conditions in a subject, comprising administering to the subject a prophylactic and / or therapeutically effective amount of fiber Lysogen.

In another aspect, the invention relates to: Item 12. A method of preventing and / or treating atherosclerotic lipid kidney injury and related conditions in a subject, comprising administering to the subject a prophylactic and / or therapeutically effective amount of fiber Lysogen.

In another aspect, the present invention relates to: Item 13. A method for preventing and / or treating renal fibrosis and related conditions caused by lipid kidney injury in a subject, comprising administering to the subject a prophylactic and / or therapeutically effective amount of Plasminogen.

Item 14. The method according to any one of Items 1-13, wherein the plasminogen can be administered in combination with one or more other drugs or treatments.

Item 15. The method of Item 14, wherein the one or more other drugs include drugs for treating hypertension, drugs for treating diabetes, drugs for treating atherosclerosis, drugs for treating chronic glomerulonephritis, drugs for treating chronic pyelonephritis, kidney disease Drugs for the treatment of symptoms, drugs for the treatment of renal insufficiency, drugs for the treatment of uremia, drugs for the treatment of kidney transplantation, drugs for the treatment of fatty liver, drugs for the treatment of cirrhosis, drugs for the treatment of obesity.

Item 16. The method according to item 15, wherein the other drugs include: lipid-lowering drugs, antiplatelet drugs, blood pressure-lowering drugs, vasodilator drugs, blood-glucose-lowering drugs, anticoagulant drugs, thrombolytic drugs, liver-protective drugs, anti- Arrhythmia drugs, cardiotonic drugs, diuretics, anti-infective drugs, antiviral drugs, immunomodulatory drugs, inflammation regulating drugs, antitumor drugs, hormone drugs, thyroxine.

Item 17. The method of Item 16, wherein the drug comprises a lipid-lowering drug: statins; fibrates; nicotinic acid; cholestyramine; anthromycin; unsaturated fatty acids such as Yishouning, Xuezhiping, and Xinmaile; algae Sodium diester; antiplatelet drugs: aspirin; pansentin; clopidogrel; cilostam; vasodilators: hydrazine and pyrrolizine; nitroglycerin and analgesic; sodium nitroprusside; alpha nitrate blockers such as oxazole Azine; Alpha receptor blockers such as phentolamine; Beta receptor stimulants such as Shuchuanling; Captopril, Enalapril; Heartache, azathione; salbutaine, long pressure Thrombolytic drugs: urokinase and streptokinase; tissue-type plasminogen initiator; single-chain urokinase-type plasminogen initiator; TNK-tissue-type plasminogen initiator Anticoagulants: Heparin; Enoxaparin; Natraparin; Bivalirudin.

Item 18. The method of any one of Items 1-17, wherein the plasminogen and sequence 2, 6, 8, 10, or 12 have at least 75%, 80%, 85%, 90%, 95%, 96% , 97%, 98%, or 99% sequence identity and still have plasminogen activity.

Item 19. The method of any one of Items 1-17, wherein the plasminogen is based on the sequence 2, 6, 8, 10, or 12, adding, deleting, and / or replacing 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1- 5, 1-4, 1-3, 1-2, 1 amino acid, and still has plasminogen activity.

Item 20. The method of any one of Items 1 to 19, wherein the plasminogen is a protein comprising a plasminogen active fragment and still having plasminogen activity.

Item 21. The method of any one of Items 1-20, wherein the plasminogen is selected from the group consisting of Glu-plasminogen, Lys-plasminogen, small plasminogen, micro-plasminogen, delta-fiber Lysogen or their variants that retain plasminogen activity.

Item 22. The method of any one of Items 1-21, wherein the plasminogen is natural or synthetic human plasminogen, or a variant or fragment thereof that still retains plasminogen activity.

Item 23. The method of any one of Items 1-21, wherein the plasminogen is a human plasminogen ortholog or a variant that still retains plasminogen activity from a primate or rodent Body or fragment.

Item 24. The method according to any one of items 1 to 23, wherein the amino acid of the plasminogen is shown in the sequence 2, 6, 8, 10, or 12.

Item 25. The method of any one of Items 1-24, wherein the plasminogen is human natural plasminogen.

Item 26. The method of any one of Items 1-25, wherein the subject is a human.

Item 27. The method of any one of Items 1-26, wherein the subject is deficient or lacks plasminogen.

Item 28. The method of item 27, wherein the deficiency or absence is innate, secondary, and / or local.

In another aspect, the invention relates to: item 29. a plasminogen for use in the method of any one of items 1-28.

In another aspect, the invention relates to: item 30. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and plasminogen for use in the method of any one of items 1-28.

In another aspect, the invention relates to: Item 31. A prophylactic or therapeutic kit comprising: (i) plasminogen for use in the method of any one of items 1-28 and (ii) For delivering the plasminogen to the subject's means.

Item 32. The kit according to item 31, wherein the component is a syringe or a vial.

Item 33. The kit of item 31 or 32, further comprising a label or an instruction manual indicating that the plasminogen is administered to the subject to perform any of the items 1 to 28 Mentioned method.

In another aspect, the invention relates to: Item 34. An article of manufacture comprising: a container containing a label; and comprising (i) a plasminogen for use in the method of any of items 1-28 or comprising plasmin A pharmaceutical composition of zymogen, wherein the label indicates that the plasminogen or composition is administered to the subject to perform the method of any one of items 1-28.

Item 35. The kit of any one of Items 31-33 or the article of Item 34, further comprising one or more components or containers containing other drugs.

Item 36. The kit or article of item 35, wherein the other drug is selected from the group consisting of a lipid-lowering drug, an antiplatelet drug, a blood pressure-lowering drug, a vasodilator drug, a blood-glucose-lowering drug, an anticoagulant drug, and a thrombolytic drug, Hepatoprotective drugs, antiarrhythmic drugs, cardiotonic drugs, diuretics, anti-infective drugs, antiviral drugs, immunomodulatory drugs, inflammation regulating drugs, antitumor drugs, hormone drugs, thyroxine.

The invention also relates to the use of plasminogen for carrying out the method of any one of items 1-28.

The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, a kit for use in the method of any one of items 1-28.

The invention also relates to the prevention and / or treatment of disorders of fat metabolism and related conditions in a subject.

In one aspect, the present invention relates to a method of preventing and / or treating adipose metabolic disorders and related conditions in a subject, comprising administering to the subject a prophylactic and / or therapeutically effective amount of plasminogen, wherein the subject is susceptible to Suffering from fat metabolism disorders, suffering from fat metabolism disorders, or suffering from other diseases with fat metabolism disorders. The invention also relates to the use of plasminogen for the prevention and / or treatment of disorders of fat metabolism and related conditions in a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for preventing and / or treating a subject's fat metabolism disorder and its related disorders. Further, the present invention relates to plasminogen for preventing and / or treating a subject's fat metabolism disorder and its related disorders. The present invention also relates to plasminogen-containing drugs, pharmaceutical compositions, preparations, and kits for preventing and / or treating a subject's fat metabolism disorder and related disorders.

In some embodiments, the fat metabolism disorder is an endocrine disorder disease, a glucose metabolism disease, a liver disease, a kidney disease, a cardiovascular disease, an intestinal disease, a thyroid disease, a gallbladder or biliary disease, obesity, alcohol consumption, drug treatment Disturbance of or accompanying fat metabolism. In some embodiments, the fat metabolism disorder is hypertension, diabetes, chronic hepatitis, cirrhosis, kidney damage, chronic glomerulonephritis, chronic pyelonephritis, renal syndrome, renal insufficiency, kidney transplantation, uremia, thyroid Impaired function, obstructive cholecystitis, obstructive cholangitis, or metabolic disorders caused by or accompanied by medication or hormone therapy. In some embodiments, the fat metabolism disorder is hyperlipidemia, hyperlipoproteinemia, fatty liver, atherosclerosis, obesity, organ fat deposition. In still other embodiments, the atherosclerosis includes aortic atherosclerosis, coronary atherosclerosis, cerebral atherosclerosis, renal atherosclerosis, hepatic atherosclerosis, mesenteric atherosclerosis , Lower extremity atherosclerosis.

In yet another aspect, the invention relates to a method for preventing and / or reducing abnormal deposition of fat in a body tissue or organ of a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for preventing and / or reducing abnormal deposition of fat in a body tissue and organ of a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for preventing and / or reducing abnormal deposition of fat in a body tissue and organ of a subject. Further, the present invention relates to plasminogen for preventing and / or reducing abnormal deposition of fat in a body tissue and organ of a subject. The invention also relates to a medicament, a pharmaceutical composition, a preparation and a kit containing plasminogen for preventing and / or reducing abnormal deposition of fat in a body tissue and organ of a subject.

In yet another aspect, the present invention relates to a method of preventing and / or treating a condition caused by abnormal deposition of fat in a body tissue or organ of a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for the prevention and / or treatment of disorders caused by abnormal deposition of fat in body tissues and organs of a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for preventing and / or treating a condition caused by abnormal deposition of fat in a body tissue or organ of a subject. Further, the present invention also relates to a medicament, a pharmaceutical composition, a preparation, and a kit comprising plasminogen for preventing and / or treating a condition caused by abnormal deposition of fat in a body tissue or organ of a subject.

In some embodiments, the abnormal deposition of fat in body tissues and organs refers to abnormal deposition of fat in blood, subcutaneous tissues, blood vessel walls, and internal organs. In some embodiments, conditions caused by abnormal deposition of fat in body tissues and organs include obesity, hyperlipidemia, hyperlipoproteinemia, fatty liver, atherosclerosis, lipid heart damage, lipid kidney damage , Lipid islet damage.

In yet another aspect, the present invention relates to a method of preventing and / or treating a disorder caused by a disorder of fat metabolism in a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for the prevention and / or treatment of conditions caused by disorders of fat metabolism in a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for preventing and / or treating a disorder caused by a disorder of fat metabolism in a subject. Further, the present invention relates to plasminogen for preventing and / or treating a disorder caused by a disorder of fat metabolism in a subject. The present invention also relates to plasminogen-containing drugs, pharmaceutical compositions, preparations, and kits for preventing and / or treating conditions caused by disorders of fat metabolism in a subject. In some embodiments, the conditions include obesity, hyperlipidemia, hyperlipoproteinemia, fatty liver, atherosclerosis, lipid heart tissue damage, and lipid kidney damage.

In yet another aspect, the present invention relates to a method of treating a disease in a subject by reducing adiposity, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for the treatment of a subject's disease by reducing the abnormal deposition of fat. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for treating a disease in a subject by reducing the abnormal deposition of fat. Further, the present invention relates to plasminogen for treating a subject's disease by reducing adiposity. The present invention also relates to a medicament, a pharmaceutical composition, a preparation, and a kit comprising plasminogen for treating a disease in a subject by reducing abnormal deposition of fat.

In some embodiments, the diseases include atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, fatty liver, cirrhosis, cerebral ischemia, cerebral infarction, renal insufficiency, renal syndrome, renal insufficiency, Obesity.

In yet another aspect, the invention relates to a method of preventing and / or treating lipid damage to a tissue or organ of a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for the prevention and / or treatment of lipid damage in tissues and organs of a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for preventing and / or treating lipid damage in tissues and organs of a subject. Further, the present invention also relates to plasminogen for preventing and / or treating lipid damage in tissues and organs of a subject. The present invention also relates to a medicament, a pharmaceutical composition, a preparation, and a kit containing plasminogen for preventing and / or treating lipid damage of tissues and organs of a subject.

In some embodiments, the tissue organ includes arterial wall, heart, liver, kidney, pancreas.

In yet another aspect, the invention relates to a method of improving hyperlipidemia in a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for improving hyperlipidemia in a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation and a kit for improving hyperlipidemia in a subject. Further, the present invention relates to plasminogen for improving hyperlipidemia in a subject. The invention also relates to a medicament, a pharmaceutical composition, a preparation, and a kit containing plasminogen for improving hyperlipidemia in a subject.

In some embodiments, the hyperlipidemia is selected from one or more of the following: hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, and low-high-density lipoproteinemia.

In yet another aspect, the invention relates to a method of reducing the risk of atherosclerosis in a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for reducing the risk of atherosclerosis in a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a product, and a kit for reducing the risk of atherosclerosis in a subject. Further, the present invention relates to plasminogen for reducing the risk of atherosclerosis in a subject. The invention also relates to plasminogen-containing drugs, pharmaceutical compositions, products, and kits for reducing the risk of atherosclerosis in a subject.

In some embodiments, the subject has hypertension, obesity, diabetes, chronic hepatitis, cirrhosis, kidney damage, chronic glomerulonephritis, chronic pyelonephritis, renal syndrome, renal insufficiency, kidney transplantation, Uremia, hypothyroidism, obstructive cholecystitis or obstructive cholangitis, or the subject is taking a drug or hormone that affects fat metabolism. In some embodiments, the plasminogen reduces the risk of atherosclerosis in a subject by one or more selected from the group consisting of: lowering total cholesterol levels in blood, triglyceride levels, low density lipoprotein levels, increasing High-density lipoprotein levels in blood.

In yet another aspect, the invention relates to a method of treating a disease by ameliorating hyperlipidemia in a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for the treatment of a disease by improving hyperlipidemia in a subject. The invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for treating a disease by improving hyperlipidemia in a subject. Further, the present invention also relates to plasminogen for treating a disease by improving hyperlipidemia in a subject. The present invention also relates to a medicament, a pharmaceutical composition, a preparation, and a kit containing plasminogen for treating a disease by improving hyperlipidemia in a subject.

In some embodiments, the conditions include diabetes, hypertension, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, chronic hepatitis, fatty liver, cirrhosis, insufficient cerebral blood supply, cerebral ischemia, cerebral infarction , Chronic nephritis, chronic pyelonephritis, renal insufficiency, renal syndrome, uremia, obesity.

In yet another aspect, the invention relates to a method of preventing and / or treating a hyperlipidemia-related disorder in a subject, comprising administering to the subject an effective amount of plasminogen. The invention also relates to the use of plasminogen for the prevention and / or treatment of hyperlipidemia-related disorders in a subject. The present invention also relates to the use of plasminogen in the preparation of a medicament, a pharmaceutical composition, a preparation, and a kit for preventing and / or treating a hyperlipidemia-related disorder in a subject. Further, the present invention also relates to plasminogen for preventing and / or treating hyperlipidemia-related disorders in a subject. The present invention also relates to plasminogen-containing drugs, pharmaceutical compositions, preparations, and kits for preventing and / or treating hyperlipidemia-related disorders in a subject. In some embodiments, the conditions include diabetes, hypertension, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, chronic hepatitis, fatty liver, cirrhosis, insufficient cerebral blood supply, cerebral ischemia, cerebral infarction , Chronic nephritis, chronic pyelonephritis, renal insufficiency, renal syndrome, uremia, obesity.

In any of the above embodiments of the invention, the plasminogen can be administered in combination with one or more other drugs or treatment methods. In some embodiments, the one or more other drugs include drugs for the treatment of hypertension, drugs for the treatment of diabetes, drugs for the treatment of atherosclerosis, drugs for the treatment of chronic glomerulonephritis, drugs for the treatment of chronic pyelonephritis, and drugs for the treatment of renal disorders Drugs, drugs for the treatment of renal insufficiency, drugs for the treatment of uremia, drugs for the treatment of kidney transplants, drugs for the treatment of fatty liver, drugs for the treatment of liver cirrhosis, drugs for the treatment of obesity. In some embodiments, the other drugs include: lipid-lowering drugs, anti-platelet drugs, blood pressure-lowering drugs, vasodilator drugs, blood glucose-lowering drugs, anticoagulant drugs, thrombolytic drugs, liver-protective drugs, antiarrhythmic drugs, Cardiotonic drugs, diuretics, anti-infective drugs, antiviral drugs, immunomodulatory drugs, inflammation regulating drugs, antitumor drugs, hormone drugs, thyroxine. In some further embodiments, the drugs include lipid-lowering drugs: statins; fibrates; nicotinic acid; cholestyramine; anthromycin; unsaturated fatty acids such as Yishouning, Xuezhiping and Xinmaile; alginic acid Diester sodium; Antiplatelet drugs: Aspirin; Pansentin; Clopidogrel; Cilostatin; Vasodilators: Hydrazine; Nitroglycerin and analgesics; Sodium nitroprusside; Alpha nitrate blockers such as prazosin ; Alpha receptor blockers such as phentolamine; Beta receptor stimulants such as Shuchuanling; Captopril, Enalapril; Heartache, azathione; Salbutaine, Changwending , Prostaglandin, atrial natriuretic peptide; thrombolytic drugs: urokinase and streptokinase; tissue-type plasminogen initiator; single-chain urokinase-type plasminogen initiator; TNK-tissue-type plasminogen initiator; Anticoagulants: Heparin; Enoxaparin; Natraparin; Bivalirudin.

In any of the above embodiments of the invention, the plasminogen may have at least 75%, 80%, 85%, 90%, 95%, 96%, 97% of the sequence 2, 6, 8, 10, or 12 %, 98% or 99% sequence identity and still have plasminogen activity. In some embodiments, the plasminogen is added, deleted, and / or substituted on the basis of the sequence 2, 6, 8, 10 or 12, 1-100, 1-90, 1-80, 1-70 , 1-60, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1 -3, 1-2, 1 amino acid, and still has plasminogen activity.

In some embodiments, the plasminogen is a protein comprising a plasminogen active fragment and still having plasminogen activity. In some embodiments, the plasminogen is selected from Glu-plasminogen, Lys-plasminogen, small plasminogen, micro-plasminogen, delta-plasminogen, or a retention thereof Variants of plasminogen activity. In some embodiments, the plasminogen is a natural or synthetic human plasminogen, or a variant or fragment thereof that still retains plasminogen activity. In some embodiments, the plasminogen is a human plasminogen ortholog or a variant or fragment thereof that still retains plasminogen activity from a primate or rodent. In some embodiments, the amino acid of the plasminogen is represented by the sequence 2, 6, 8, 10, or 12. In some embodiments, the plasminogen is human natural plasminogen.

In some embodiments, the subject is a human. In some embodiments, the subject is lacking or lacking plasminogen. In some embodiments, the deficiency or deletion is innate, secondary, and / or local.

In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier and plasminogen for use in the aforementioned method. In some embodiments, the kit may be a prophylactic or therapeutic kit comprising: (i) plasminogen used in the aforementioned method and (ii) used to deliver the plasminogen to all The subject's means. In some embodiments, the component is a syringe or a vial. In some embodiments, the kit further comprises a label or an instruction manual that indicates that the plasminogen is administered to the subject to perform any of the foregoing methods.

In some embodiments, the article of manufacture comprises: a container containing a label; and a pharmaceutical composition comprising (i) plasminogen or a plasminogen for use in the foregoing method, wherein the label indicates that the fiber The lysogen or composition is administered to the subject to perform any of the foregoing methods.

In some embodiments, the kit or article of manufacture further comprises one or more components or containers containing other drugs. In some embodiments, the other drug is selected from the group consisting of a lipid-lowering drug, an anti-platelet drug, a blood-pressure-lowering drug, a vasodilator drug, a blood-sugar-lowering drug, an anticoagulant drug, a thrombolytic drug, a liver-protective drug, and an anticardiac rhythm Arrhythmic drugs, cardiotonic drugs, diuretic drugs, anti-infective drugs, antiviral drugs, immunomodulatory drugs, inflammation regulating drugs, antitumor drugs, hormone drugs, thyroxine.

In some embodiments of the foregoing methods, the plasminogen is administered systemically or locally, preferably by the following route: intravenous, intramuscular, subcutaneous administration of plasminogen for treatment. In some embodiments of the foregoing methods, the plasminogen is administered in combination with a suitable polypeptide carrier or stabilizer. In some embodiments of the foregoing methods, the plasminogen is at 0.0001-2000 mg / kg, 0.001-800 mg / kg, 0.01-600 mg / kg, 0.1-400 mg / kg, 1-200 mg / kg, 1-100 mg per day / kg, 10-100mg / kg (calculated per kilogram of body weight) or 0.0001-2000mg / cm2, 0.001-800mg / cm2, 0.01-600mg / cm2, 0.1-400mg / cm2, 1-200mg / cm2, 1-100mg / cm2, 10-100 mg / cm2 (calculated as body surface area per square centimeter), preferably at least once, and preferably at least daily.

The present invention clearly covers all combinations of technical features belonging to the embodiments of the present invention, and the technical solutions after these combinations have been explicitly disclosed in this application, just as the above technical solutions have been separately and explicitly disclosed. In addition, the present invention also explicitly covers the combinations between the various embodiments and their elements, and the combined technical solutions are explicitly disclosed herein.

Definition

The "lipid metabolism disorder" in the present invention is also called "abnormal fat metabolism" and "lipid metabolism disorder", which is a general term for clinical or pathological manifestations caused by abnormality, disorder or disorder of fat metabolism. In this article, "dyslipidemia", "abnormal fat metabolism", and "dyslipidemia" are used interchangeably. In the present invention, "fat metabolism", "lipid metabolism", and "lipid metabolism" can be used interchangeably.

The "lipid metabolism disorder-related disorder" is a general term for disorders related to fat metabolism disorder. The correlation may be related to etiology, pathogenesis, pathological manifestations, clinical symptoms, and / or treatment principles.

"Blood lipids" is a general term for triglycerides, cholesterol, and phospholipids. Lipoproteins are spherical macromolecular complexes composed of apolipoproteins and blood lipids. Because lipoproteins contain different components of cholesterol and triglycerides and different densities, Divided into 5 categories: chylomicrons (CM) very low density lipoprotein (VLDL) medium density lipoprotein (IDL) low density lipoprotein (LDL) high density lipoprotein (HDL). According to the level of lipid risk, the most common types of abnormal lipoproteinemia in clinical practice: hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, and low-density lipoproteinemia. Secondary dyslipidemia is seen in diabetes, hypothyroidism, nephrotic syndrome, kidney transplantation, severe liver disease, obstructive biliary tract disease, obesity, alcohol consumption, medication, such as estrogen therapy, etc., if secondary dyslipidemia can be ruled out Consider primary dyslipidemia.

"Hyperlipidemia" refers to a pathological condition in which blood lipid components such as cholesterol, triglycerides, phospholipids, and non-lipidated fatty acid are increased in plasma.

A "hyperlipidemia-related disorder" refers to a disorder that is related to the cause, pathogenesis, pathological manifestations, clinical symptoms, and / or therapeutic principles of hyperlipidemia. Preferably, the conditions include, but are not limited to, diabetes, hypertension, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, chronic hepatitis, fatty liver, cirrhosis, insufficient cerebral blood supply, cerebral ischemia, cerebral infarction, chronic Nephritis, chronic pyelonephritis, renal insufficiency, kidney syndrome, uremia, obesity.

One or more lipid abnormalities in plasma due to abnormal fat metabolism or function are called "hyperlipidemia", "hyperlipidemia" or "dyslipidemia".

Because lipids are insoluble or slightly soluble in water, they must be combined with proteins to form lipoproteins to function in the blood loop. Therefore, hyperlipidemia is often a reflection of "hyperlipoproteinemia."

The "hyperlipidemia-related disorder" of the present invention may also be referred to as "hyperlipidemia-related disorder" and "hyperlipoproteinemia-related disorder".

"Fat liver" refers to the pathological changes of excessive fat accumulation in liver cells caused by various reasons. It can be an independent disease or caused by other reasons, such as obese fatty liver, alcoholic fatty liver, and fast-fat fat. Liver, malnutrition fatty liver, diabetic fatty liver, drug-induced fatty liver, etc.

In the case of fatty liver, lipid droplets in hepatocytes increase, making the liver cells fatty and degenerate, and the nuclei are squeezed off-center. The metabolism of fat is carried out in mitochondria. The transport of fat to the outside of the cell mainly passes through the smooth endoplasmic reticulum. The accumulation of fat in liver cells further aggravates the burden of mitochondria and endoplasmic reticulum and reduces its function, which in turn affects other nutrients, hormones, Vitamin metabolism. Long-term degeneration of hepatocytes can lead to regenerative disorders and necrosis of hepatocytes, leading to liver fibrosis and cirrhosis.

"Atherosclerosis" is a chronic, progressive arterial disease in which fat deposits in the arteries partially or completely block the blood flow at the time of onset. Atherosclerosis occurs when the smooth, solid arterial intima becomes rough, thickened, and clogged with fat, fibrin, calcium, and cellular debris. Atherosclerosis is a gradual process. When the concentration of lipids in the blood increases greatly, fat streaks form along the walls of the arteries. These streaks cause fat and cholesterol to deposit, and these deposits cling to the original smooth arterial intima, forming nodules. Fibrotic scar tissue grows beneath these nodules, leading to calcium deposition. The deposited calcium gradually evolved into a hard, chalky thin film called atheroma. This permanent film inside the arteries hinders the normal expansion and contraction of the arteries, which slows down the blood flow in the arteries, which can easily form blood clots that prevent or prevent blood from flowing through the arteries.

The exact cause of atherosclerosis has not been determined, but important causative factors have been identified: hyperlipidemia, hypertension, a history of smoking, and a family history of atherosclerosis (before 60 years of age) Or diabetes. Hyperlipidemia can promote the formation of fat stripes. Hypertension exerts a certain constant force on the arteries, which accelerates the process of arterial occlusion and sclerosis, thus increasing the prevalence of atherosclerosis. Smoking can cause arteries to constrict and restrict blood flow, thus creating conditions for arterial occlusion. Diabetes can also contribute to atherosclerosis, especially for very small arteries.

As far as atherosclerosis is concerned, people don't feel any symptoms. The disease is only discovered when an artery connected to an important organ in the body is blocked. Symptoms due to blocked arteries in this organ are more pronounced. For example, if the heart's blood-supplying arteries are partially blocked, people may feel angina; but if they are completely blocked, it can lead to heart disease (the death of heart tissue supplied by the blocked arteries). If atherosclerosis affects the cerebral arteries, people will feel dizzy, blurry, and syncope, and may even cause strokes (death of brain tissue supplied by blocked arteries, causing nerve damage, such as paralysis of limbs controlled by dead brain tissue ). Blocked arteries to the kidneys can also cause kidney failure. Blocked blood vessels to the eye can cause blindness. Arterial occlusion of the extremities may cause lesions in each limb.

Atherosclerosis is the main cause of coronary heart disease, cerebral infarction, and peripheral vascular disease. Impaired lipid metabolism is the basis of atherosclerotic lesions. It is characterized by the involvement of arterial lesions starting from the intima. Generally, lipids and complex sugars accumulate, bleeding and thrombosis first, followed by fibrous tissue hyperplasia and calcium deposits. The gradual metamorphosis and calcification of the artery lead to thickening and hardening of the arterial wall and narrowing of the vascular cavity. Lesions often involve the large and medium muscular arteries, and once they develop enough to block the arterial cavity, the tissues or organs supplied by the arteries will be ischemic or necrotic.

Atherosclerosis is a systemic disease. The occurrence of atherosclerotic lesions in the blood vessels of an organ means that the same lesions may already exist in blood vessels elsewhere; similarly, the occurrence of vascular events in one organ means that vascular events occur elsewhere. Increased risk.

Figure 1 Observation of Sirius Red staining on kidneys of 3% cholesterol hyperlipidemia model mice 30 days after plasminogen administration. A is a blank control group, B is a PBS control group, C is a plasminogen group, and D is a quantitative analysis result. The results showed that the collagen deposition (marked by the arrow) of the kidney in the plasminogen group was significantly less than that in the PBS control group, and the statistical difference was significant; the fibrosis in the plasminogen group returned to normal levels. This shows that plasminogen can effectively reduce renal fibrosis in 3% cholesterol hyperlipidemia model mice.

Figure 2 Observation results of kidney oil red O in 3% cholesterol hyperlipidemia model mice after plasminogen administration for 30 days. A is a blank control group, B is a PBS control group, C is a plasminogen group, and D is a quantitative analysis result. The results showed that the fat deposition (marked with an arrow) in the kidney of the plasminogen-treated mice was significantly less than that in the PBS-administered control group, and the statistical analysis was significantly different; Rats are similar. This shows that plasminogen can reduce the deposition of fat in the kidney of hyperlipidemia model mice, thereby reducing kidney damage caused by fat deposition.

Fig. 3 Observation results of liver oil red O staining in a 16-week hyperlipidemia model mouse after plasminogen administration for 30 days. A is the control group of PBS, B is the plasminogen group, and C is the result of quantitative analysis. The results showed that liver fat deposition in the plasminogen-administered group was significantly less than that in the PBS-administered control group, and the statistical difference was significant in the quantitative analysis (* indicates P <0.05). This shows that plasminogen can improve the deposition of fat in the liver of hyperlipidemia model mice.

Fig. 4 Observation results of aortic sinus oil red O staining after 30 days of plasminogen administration in mice with hyperlipidemia at 16 weeks. A and C are the control group of PBS, B and D are the group of plasminogen and E is the result of quantitative analysis. The results showed that the aortic sinus fat deposition of the mice given the plasminogen group was significantly less than that of the vehicle given the PBS control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can improve the deposition of fat in the aortic sinus of hyperlipidemia model mice.

Figure 5 Representative picture of aortic sinus HE staining after 16 weeks of hyperlipidemia model mice given plasminogen. A and C are the PBS control group, B and D are the plasminogen group. The results showed that foam cells were deposited in the aortic wall of the control group with PBS (pointed by arrows), and plaque deposition was severe; only mild foam cells were deposited in the aortic wall of the plasminogen group, and No obvious atherosclerotic plaque deposition was found, and the aortic injury to the plasminogen group was mild. This shows that plasminogen can improve the damage caused by lipid deposition in the inner wall of aortic sinus in hyperlipidemia model mice.

Figure 6 Immunohistochemical staining of cardiac fibrin in mice with 16 weeks of hyperlipidemia model after 30 days of plasminogen administration. A is the control group of PBS, B is the plasminogen group, and C is the result of quantitative analysis. The results showed that the positive expression of cardiac fibrin in mice given the plasminogen group was significantly less than that in the PBS control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can reduce the heart damage caused by hyperlipidemia.

Figure 7 Representative picture of cardiac IgM immunostaining after 16 weeks of hyperlipidemia model mice given plasminogen. A is the control group of PBS, B is the plasminogen group. The results showed that the positive expression of IgM in the heart of the mice given the plasminogen group was significantly less than that in the vehicle-administered PBS control group, indicating that plasminogen can reduce the heart damage caused by hyperlipidemia.

Figure 8 Representative picture of heart Sirius red staining after 16 weeks of hyperlipidemia model mice given plasminogen. A is the control group of PBS, B is the plasminogen group. The results showed that collagen deposition in the plasminogen-treated group was significantly less than that in the vehicle-treated PBS control group, indicating that plasminogen can reduce cardiac fibrosis in hyperlipidemia model mice.

Figure 9 Results of serum troponin measurement in mice with hyperlipidemia at 16 weeks after plasminogen administration for 30 days. The results showed that the serum cardiac troponin concentration in the vehicle-administered PBS control group was significantly higher than that in the plasminogen-administered group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can significantly repair the heart injury of hyperlipidemia.

Figure 10 Serum high-density lipoprotein cholesterol test results in 3% cholesterol hyperlipidemia model mice after 10 and 20 days of plasminogen administration. The results showed that the serum HDL-C concentration of the plasminogen-administered mice after plasminogen administration was significantly higher than that of the vehicle-treated PBS control group, and the HDL-C concentrations were statistically calculated after 10 and 20 days of administration. The difference is extremely significant (** indicates P <0.01). This shows that plasminogen can effectively increase the content of high-density lipoprotein cholesterol in the serum of hyperlipidemia model mice, and improve blood lipid disorders in hyperlipidemia model mice.

Figure 11 Serum total cholesterol test results in a 3% cholesterol hyperlipidemia model mouse after plasminogen administration for 20 days. The results showed that the total cholesterol concentration of the mice given the plasminogen group was significantly lower than that of the vehicle given the PBS control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can reduce the total cholesterol content in the serum of hyperlipidemia model mice, and has the function of reducing blood lipids.

Figure 12 Serum low-density lipoprotein cholesterol test results in 3% cholesterol hyperlipidemia model mice after plasminogen administration for 20 days. The results showed that the concentration of LDL-C in the plasminogen-administered group was significantly lower than that in the PBS-administered control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can reduce the content of low density lipoprotein cholesterol in the serum of hyperlipidemia model mice, and has the function of improving hyperlipidemia.

Figure 13 Serum atherosclerosis index test results of 3% cholesterol hyperlipidemia model mice given plasminogen for 20 days. The results showed that the atherosclerosis index of the mice given the plasminogen group was significantly lower than that of the vehicle given the PBS control group, and the statistical difference was very significant (** indicates P <0.01). This shows that plasminogen can effectively reduce the risk of atherosclerosis in hyperlipidemia model mice.

Figure 14 Serum cardiac risk index results of 3% cholesterol hyperlipidemia model mice after plasminogen administration for 20 days. The results showed that the CRI of the plasminogen-treated group was significantly smaller than that of the vehicle-treated PBS control group, and the statistical difference was extremely significant (** indicates P <0.01). This shows that plasminogen can effectively reduce the risk of heart disease in hyperlipidemia model mice.

Figure 15 Liver oil red O staining pictures of diabetic mice administered with plasminogen for 35 to 24 weeks. The results showed that the area of lipid deposition in the liver of the plasminogen-treated mice was significantly smaller than that in the PBS-administered control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can reduce the deposition of fat in the liver of diabetic mice.

Figure 16 HE staining of aorta after 24-25 week-old diabetic mice given plasminogen. A and C are the PBS control group, B and D are the plasminogen group. The results showed that foam cells were deposited on the vessel wall of the PBS control group with the solvent (arrows marked), the middle elastic membrane was disorderly arranged, the blood vessel wall was thickened, and the wall was uneven. The structure of the middle elastic membrane in the plasminogen group was regular, showing Wavy, uniform thickness of vessel wall. It shows that the injection of plasminogen can repair the aortic damage caused by diabetes.

Figure 17 Representative picture of ventricular oil red O staining after 26 days of diabetic mice given plasminogen 35 days. A is the control group of PBS, B is the plasminogen group. The results showed that ventricular lipid deposition (marked with an arrow) in the plasminogen-treated mice was significantly less than that in the vehicle-treated PBS control group. This shows that plasminogen can reduce ventricular lipid deposition in diabetic mice and promote repair of ventricular damage.

Figure 18: Results of detection of high-density lipoprotein cholesterol in serum after plasminogen administration for 26 days in 26-week-old diabetic mice. The results showed that after continuous injection of human-derived plasmin source for 35 days in diabetic mice, the serum HDL-C content in the plasminogen-treated mice was higher than that in the vehicle-treated PBS control group, and the statistical difference was significant. This shows that plasminogen injection can promote the increase of serum high-density lipoprotein cholesterol and improve the blood lipid disorders in diabetic mice.

Figure 19 Results of detection of low-density lipoprotein cholesterol (LDL-C) in serum of dialysis mice 24-24 weeks of age after 31 days of administration of plasminogen. The results showed that after 31 days of continuous injection of human-derived plasmin source in diabetic model mice, the LDL-C content in the serum of the plasminogen-treated mice was lower than that in the vehicle-treated PBS control group, and the statistical difference was close to significant (P = 0.1 ). This shows that plasminogen can reduce the content of low density lipoprotein cholesterol in the serum of diabetic mice.

Figure 20 Results of serum total cholesterol measurement in mice with ApoE atherosclerosis model after 30 days of plasminogen administration. The results showed that the total cholesterol concentration of the mice given the plasminogen group was significantly lower than that of the vehicle given the PBS control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can reduce the total cholesterol content in the serum of ApoE atherosclerosis model mice and improve the blood lipid disorders in atherosclerosis model mice.

Figure 21 Results of serum triglyceride detection in ApoE atherosclerotic model mice after 30 days of plasminogen administration. The results showed that the concentration of triglyceride in the plasminogen-treated mice was significantly lower than that in the PBS-treated control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can reduce the triglyceride content in the serum of ApoE atherosclerotic model mice, and improve blood lipid disorders in atherosclerotic model mice.

Figure 22 ApoE atherosclerosis model mice. Serum low density lipoprotein cholesterol test results 30 days after plasminogen administration. The results showed that the concentration of LDL-C in the plasminogen-administered group was significantly lower than that in the PBS-administered control group, and the statistical difference was significant (* indicates P <0.05). This shows that plasminogen can reduce the content of low-density lipoprotein cholesterol in the serum of ApoE atherosclerotic model mice, and improve blood lipid disorders in atherosclerotic model mice.

Figure 23 A representative picture of liver oil red O staining in ApoE atherosclerotic model mice 30 days after plasminogen administration. A is the control group of PBS, B is the plasminogen group, and C is the result of quantitative analysis. The results showed that liver fat deposition in the plasminogen-administered group was significantly less than that in the PBS-administered control group, and the statistical difference was significant in the quantitative analysis (* indicates P <0.05). This shows that plasminogen can reduce fat deposition in the liver of atherosclerotic model mice.

Fig. 24 Representative picture of aortic sinus oil red O staining in 30 days after plasminogen administration in ApoE atherosclerosis model mice. A is the control group of PBS, B is the plasminogen group. The results showed that the aortic sinus fat deposition in the plasminogen-treated mice was significantly less than that in the vehicle-treated PBS control group. This shows that plasminogen can improve the deposition of fat in the aortic sinus of atherosclerotic model mice.

Figure 25 Representative picture of aortic sinus Sirius red staining after 30 days of plasminogen administration in 16-week-old hyperlipidemia model mice. A and C are the PBS control group, B and D are the plasminogen group. The results showed that the area of collagen deposition (arrows) on the inner wall of the aortic sinus vessels in the plasminogen group was significantly smaller than that in the PBS control group, indicating that plasminogen could reduce the aortic sinus fibers in the hyperlipidemia model mice. Standardization.

Fig. 26 Statistical results of cardiac coefficients of ApoE atherosclerosis model mice after plasminogen administration for 30 days. The results showed that the cardiac organ coefficients of the mice given the plasminogen group were significantly lower than those of the PBS control group. This shows that plasminogen can improve cardiac compensatory hypertrophy caused by heart injury in ApoE atherosclerotic model mice.

Detailed description of the invention

Plasmin is a key component of the plasminogen initiation system (PA system). It is a broad-spectrum protease capable of hydrolyzing several components of the extracellular matrix (ECM), including fibrin, gelatin, fibronectin, laminin, and proteoglycans ^[9] . In addition, plasmin can initiate some metalloproteinase precursors (pro-MMPs) to form active metalloproteinases (MMPs). Therefore, plasmin is considered to be an important upstream regulator of extracellular proteolysis ^[10,11] . Plasmin is formed from plasminogen through two physiological PAs: tissue-type plasminogen initiator (tPA) or urokinase-type plasminogen initiator (uPA). Due to the relatively high level of plasminogen in plasma and other body fluids, it is traditionally believed that the regulation of the PA system is mainly achieved through the synthesis and activity levels of PAs. The synthesis of PA system components is strictly regulated by different factors, such as hormones, growth factors and cytokines. In addition, there are specific physiological inhibitors of plasmin and PAs. The main inhibitor of plasmin is α2-antiplasmin. The activity of PAs was simultaneously inhibited by both plasminogen initiator inhibitor-1 (PAI-1) of uPA and tPA and plasminogen initiator inhibitor-2 (PAI-2), which mainly inhibits uPA. UPA-specific cell surface receptor (uPAR) with direct hydrolytic activity on some cell surfaces ^[12,13] .

Plasminogen is a single-chain glycoprotein consisting of 791 amino acids and a molecular weight of approximately 92 kDa ^[14,15] . Plasminogen is mainly synthesized in the liver and is abundantly present in extracellular fluid. Plasminogen content in plasma is about 2 μM. Thus plasminogen is a huge potential source of proteolytic activity in tissues and body fluids ^[16,17] . There are two molecular forms of plasminogen: glutamate-plasminogen and lysine-plasminogen. Plasminogen, a naturally secreted and uncleavable form, has an amino-terminal (N-terminal) glutamate and is therefore called glutamate-plasminogen. However, in the presence of plasmin, glutamate-plasminogen is hydrolyzed to lysine-plasminogen at Lys76-Lys77. Compared with glutamate-plasminogen, lysine-plasminogen has higher affinity for fibrin and can be activated by PAs at a higher rate. These two forms of plasminogen Arg560-Val561 peptide bonds can be cleaved by uPA or tPA, leading to the formation of a disulfide-linked double-chain protease plasmin ^[18] . The amino-terminal portion of plasminogen contains five homologous tricyclic rings, so-called kringles, and the carboxy-terminal portion contains a protease domain. Some kringles contain lysine binding sites that mediate the specific interaction of plasminogen with fibrin and its inhibitor α2-AP. A 38-kDa fragment of plasminogen, including kringles1-4, was recently discovered as a potent inhibitor of angiogenesis. This fragment is named angiostatin and can be produced by the hydrolysis of plasminogen by several proteases.

The main substrate of plasmin is fibrin, and the dissolution of fibrin is the key to prevent pathological thrombosis ^[19] . Plasmin also has substrate specificity for several components of ECM, including laminin, fibronectin, proteoglycan, and gelatin, suggesting that plasmin also plays an important role in ECM reconstruction [ ^{15, 20, 21]} . Indirectly, plasmin can also degrade other components of ECM by converting certain protease precursors into active proteases, including MMP-1, MMP-2, MMP-3, and MMP-9. Therefore, it has been suggested that plasmin may be an important upstream regulator of extracellular proteolysis ^[22] . In addition, plasmin has the ability to initiate certain potential forms of growth factors ^[23-25] . In vitro, plasmin can also hydrolyze components of the complement system and release chemotactic complement fragments.

"Fibrinolytic enzyme" is a very important enzyme that exists in the blood and can hydrolyze fibrin clots into fibrin degradation products and D-dimers.

"Plasminogen" is the zymogen form of plasmin, according to the sequence in swiss prot, according to the natural human plasminogen amino acid sequence (sequence 4) containing the signal peptide, it is composed of 810 amino acids, and the molecular weight is about 90kD, a glycoprotein mainly synthesized in the liver and capable of circulating in the blood. The cDNA sequence encoding this amino acid sequence is shown in Sequence 3. The full-length plasminogen contains seven domains: a serine protease domain at the C-terminus, a Pan Apple (PAp) domain at the N-terminus, and five Kringle domains (Kringle1-5). Referring to the sequence in swiss prot, its signal peptide includes residues Met1-Gly19, PAp includes residues Glu20-Val98, Kringle1 includes residues Cys103-Cys181, Kringle2 includes residues Glu184-Cys262, and Kringle3 includes residues Cys275-Cys352, Kringle4 Including residues Cys377-Cys454, Kringle5 includes residues Cys481-Cys560. According to NCBI data, the serine protease domain includes residues Val581-Arg804.

Glu-plasminogen is a natural full-length plasminogen, consisting of 791 amino acids (without a signal peptide containing 19 amino acids). The cDNA sequence encoding this sequence is shown in Sequence 1 and its amino acid sequence is shown in Sequence 2. Show. In vivo, there is also a Lys-plasminogen formed by hydrolysis of amino acids 76-77 of Glu-plasminogen. As shown in Sequence 6, the cDNA sequence encoding the amino acid sequence is as shown in Sequence 5. Show. Delta-plasminogen (δ-plasminogen) is a fragment of the full-length plasminogen without the Kringle2-Kringle5 structure, which contains only Kringle1 and the serine protease domain ^[26,27] . There are reports in the literature about delta-plasminogen. Amino acid sequence (sequence 8) ^[27] . The cDNA sequence encoding this amino acid sequence is shown in sequence 7. Mini-plasminogen is composed of Kringle5 and serine protease domain, and it is reported in the literature that it includes residue Val443-Asn791 (with the Glu residue of the Glu-plasminogen sequence without signal peptide as the starting amino acid ) ^[28] , the amino acid sequence of which is shown in Sequence 10, and the cDNA sequence encoding the amino acid sequence is shown in Sequence 9. Micro-plasminogen contains only a serine protease domain, and the literature reports that its amino acid sequence includes residues Ala543-Asn791 (starting from the Glu residue of the Glu-plasminogen sequence that does not contain a signal peptide (Starting amino acid) ^[29] , and also patent document CN102154253A reports that its sequence includes residues Lys531-Asn791 (using the Glu residue of the Glu-plasminogen sequence that does not contain a signal peptide as the starting amino acid). This patent sequence refers to the patent document CN102154253A, the amino acid sequence of which is shown in Sequence 12, and the cDNA sequence encoding the amino acid sequence is shown in Sequence 11.

The "plasmin" and "plasmin" and "plasmin" in the present invention are used interchangeably and have the same meaning; "plasminogen" and "plasminogen" and "plasminogen" Can be used interchangeably and have the same meaning.

In the present application, the "lack" of plasminogen means that the content of plasminogen in a subject is lower than that of a normal person, and is low enough to affect the normal physiological function of the subject; The meaning of "deletion" of zymogen is that the content of plasminogen in the subject is significantly lower than that of normal people, and even the expression is minimal, and only by external sources can it sustain life.

Those skilled in the art can understand that all the technical solutions of the plasminogen of the present invention are applicable to plasmin. Therefore, the technical solutions described in the present invention cover plasminogen and plasmin.

During the loop, plasminogen adopts a closed, inactive conformation, but when bound to a thrombus or cell surface, it changes to open under the mediation of a plasminogen activator (PA) Sexual conformation of active plasmin. The active plasmin can further hydrolyze the fibrin clot into fibrin degradation products and D-dimers, and then dissolve the thrombus. The PAp domain of plasminogen contains important determinants that maintain plasminogen in an inactive closed conformation, while the KR domain can bind to lysine residues present on the receptor and substrate. A variety of enzymes known as plasminogen initiators include: tissue plasminogen initiator (tPA), urokinase plasminogen initiator (uPA), kallikrein, and coagulation factor XII (Hagg Mann factor) and so on.

The "plasminogen active fragment" refers to an active fragment in plasminogen protein that can bind to a target sequence in a substrate and exert a proteolytic function. The technical scheme of the present invention relating to plasminogen covers the technical scheme of replacing plasminogen with a plasminogen active fragment. The plasminogen active fragment according to the present invention is a protein comprising a serine protease domain of plasminogen. Preferably, the plasminogen active fragment according to the present invention comprises sequence 14 and has at least 80%, 90% of sequence 14, and 90. %, 95%, 96%, 97%, 98%, 99% homology of amino acid sequence protein. Therefore, the plasminogen according to the present invention includes a protein containing the plasminogen active fragment and still maintaining the plasminogen activity.

At present, methods for measuring plasminogen in blood and its activity include: detection of tissue plasminogen initiator activity (t-PAA), detection of plasma tissue plasminogen initiator antigen (t-PAAg), Detection of plasma tissue plasminogen activity (plgA), detection of plasma tissue plasminogen antigen (plgAg), detection of plasma tissue plasminogen initiator inhibitor activity, inhibition of plasma tissue plasminogen initiator Detection of biological antigens, plasma plasmin-antiplasmin complex detection (PAP). The most commonly used detection method is the chromogenic substrate method: adding streptokinase (SK) and a chromogenic substrate to the test plasma. PLG in the test plasma is transformed into PLM by the action of SK, which acts on the hair. The color substrate was subsequently measured with a spectrophotometer, and the increase in absorbance was directly proportional to plasminogen activity. In addition, plasminogen activity in blood can also be measured using immunochemical methods, gel electrophoresis, immunoturbidimetry, and radioimmunodiffusion methods.

"Ortholog or ortholog" refers to homologs between different species, including both protein homologs and DNA homologs, also known as orthologs and orthologs. It specifically refers to proteins or genes evolved from the same ancestral gene in different species. The plasminogen of the present invention includes human natural plasminogen, and also includes plasminogen orthologs or orthologs that have plasminogen activity from different species.

A "conservative substitution variant" refers to one in which a given amino acid residue is altered without altering the overall conformation and function of the protein or enzyme. This includes, but is not limited to, those with similar properties (such as acidity, basicity, hydrophobicity, etc.) Amino acids replace amino acids in the amino acid sequence in the parent protein. Amino acids with similar properties are well known. For example, arginine, histidine, and lysine are hydrophilic basic amino acids and are interchangeable. Similarly, isoleucine is a hydrophobic amino acid and can be replaced by leucine, methionine or valine. Therefore, the similarity of two proteins or amino acid sequences with similar functions may differ. For example, based on the MEGALIGN algorithm's 70% to 99% similarity (identity). "Conservative substitution variants" also include polypeptides or enzymes that have been identified by BLAST or FASTA algorithms with more than 60% amino acid identity. It is better to be more than 75%, preferably more than 85%, or even more than 90% Is optimal and has the same or substantially similar properties or functions as the natural or parental protein or enzyme.

"Isolated" plasminogen refers to a plasminogen protein that is isolated and / or recovered from its natural environment. In some embodiments, the plasminogen is purified (1) to a purity (by weight) of greater than 90%, greater than 95%, or greater than 98%, as determined by the Lowry method, e.g., greater than 99% (By weight), (2) to an extent sufficient to obtain at least 15 residues of the N-terminal or internal amino acid sequence by using a rotating cup sequence analyzer, or (3) to homogeneity, which is achieved through the use of kaoma Blue or silver staining was determined under sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or non-reducing conditions. Isolated plasminogen also includes plasminogen prepared from recombinant cells by bioengineering techniques and isolated by at least one purification step.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein and refer to a polymeric form of an amino acid of any length, which may include genetically encoded and non-genetically encoded amino acids, chemically or biochemically modified or derivatized Amino acids, and polypeptides with modified peptide backbones. The term includes fusion proteins, including but not limited to fusion proteins with heterologous amino acid sequences, fusions with heterologous and homologous leader sequences (with or without N-terminal methionine residues); and the like.

"Percent amino acid sequence identity (%)" with respect to a reference polypeptide sequence is defined as when a gap is introduced when necessary to achieve the maximum percentage sequence identity, and any conservative substitutions are not considered as part of the sequence identity, The percentage of amino acid residues in the reference polypeptide sequence that are identical. Comparisons for the purpose of determining percent amino acid sequence identity can be accomplished in a variety of ways within the skill of the art, for example using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared. However, for the purposes of the present invention, the percent amino acid sequence identity values were generated using the sequence comparison computer program ALIGN-2.

In the case where ALIGN-2 is used to compare amino acid sequences, a given amino acid sequence A has a% amino acid sequence identity relative to a given amino acid sequence B (or can be expressed as having or containing a sequence with respect to, with, or against a given amino acid sequence A given amino acid sequence with a certain% amino acid sequence identity of B. A) is calculated as follows: fraction X / Y times 100

Where X is the number of amino acid residues that were scored the same by the sequence alignment program ALIGN-2 in the A and B alignments of the program, and where Y is the total number of amino acid residues in B. It should be appreciated that in the case where the length of the amino acid sequence A is not equal to the length of the amino acid sequence B, the% amino acid sequence identity of A relative to B will not be equal to the% amino acid sequence identity of B relative to A. Unless expressly stated otherwise, all% amino acid sequence identity values used herein were obtained using the ALIGN-2 computer program as described in the previous paragraph.

As used herein, the terms "treatment" and "treatment" refer to obtaining a desired pharmacological and / or physiological effect. The effect may be a complete or partial prevention of a disease or a symptom thereof, and / or a partial or complete cure of a disease and / or a symptom thereof, and includes: (a) preventing the disease from occurring in a subject, the subject may have The cause of the disease, but has not been diagnosed with a disease; (b) inhibiting the disease, that is, blocking its formation; and (c) reducing the disease and / or its symptoms, that is, causing the disease and / or its symptoms to subside.

The terms "individual", "subject" and "patient" are used interchangeably herein and refer to mammals, including but not limited to mice (rats, mice), non-human primates, humans, dogs, cats, Hoofed animals (for example, horses, cattle, sheep, pigs, goats) and the like.

A "therapeutically effective amount" or "effective amount" refers to an amount of plasminogen sufficient to achieve said prevention and / or treatment of a disease when administered to a mammal or other subject to treat the disease. The "therapeutically effective amount" will vary depending on the plasminogen used, the severity of the disease and / or symptoms of the subject to be treated, and the age, weight, and the like.

Preparation of plasminogen of the invention

Plasminogen can be isolated and purified from nature for further therapeutic use, or it can be synthesized by standard chemical peptide synthesis techniques. When the polypeptide is synthesized chemically, it can be synthesized via a liquid phase or a solid phase. Solid-phase peptide synthesis (SPPS), in which the C-terminal amino acid of the sequence is attached to an insoluble support, followed by the sequential addition of the remaining amino acids in the sequence, is a suitable method for plasminogen chemical synthesis. Various forms of SPPS, such as Fmoc and Boc, can be used to synthesize plasminogen. Techniques for solid-phase synthesis are described in Barany and Solid-Phase Peptide Synthesis; The Peptides: Analysis, Synthesis, Biology, p. 3-284. Vol. 2: Special Methods in Peptide Synthesis, Part A., Merrifield, et al. J Am.Chem.Soc., 85: 2149-2156 (1963); Stewart et al., Solid Phase Peptide Synthesis, 2nd ed. Pierce Chem. Co., Rockford, Ill. (1984); and Ganesan A. 2006 Mini Rev. Med Chem. 6: 3-10 and Camarero JA et al. 2005 Protein Pept Lett. 12: 723-8. In short, small insoluble porous beads are treated with functional units on which peptide chains are built. After repeated loops of coupling / deprotection, the attached solid phase free N-terminal amine is coupled to a single N-protected amino acid unit. This unit is then deprotected to reveal new N-terminal amines that can be attached to other amino acids. The peptide remains immobilized on a solid phase and is then cut off.

Standard recombinant methods can be used to produce the plasminogen of the invention. For example, a plasminogen-encoding nucleic acid is inserted into an expression vector so that it is operably linked to regulatory sequences in the expression vector. Expression control sequences include, but are not limited to, promoters (e.g., naturally associated or heterologous promoters), signal sequences, enhancer elements, and transcription termination sequences. Expression regulation may be a eukaryotic promoter system in a vector that is capable of transforming or transfecting a eukaryotic host cell (eg, a COS or CHO cell). Once the vector is incorporated into a suitable host, the host is maintained under conditions suitable for high-level expression of the nucleotide sequence and collection and purification of plasminogen.

Suitable expression vectors are usually replicated in the host organism as episomes or as an integral part of the host chromosomal DNA. Generally, expression vectors contain selection markers (e.g., ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance, or neomycin resistance) to facilitate transformation with the desired DNA sequence to foreign sources Those cells.

Escherichia coli is an example of a prokaryotic host cell that can be used to replicate a subject antibody-encoding polynucleotide. Other microbial hosts suitable for use include Bacillus, such as Bacillus subtilis and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas (Pseudomonas) species. In these prokaryotic hosts, expression vectors can also be generated that will typically contain expression control sequences (eg, origins of replication) that are compatible with the host cell. In addition, there are many known promoters, such as the lactose promoter, the tryptophan (trp) promoter, the beta-lactamase promoter, or the promoter from phage lambda. Promoters usually control expression, optionally in the case of operator sequences, and have ribosome binding site sequences, etc., to initiate and complete transcription and translation.

Other microorganisms, such as yeast, can also be used for expression. Yeasts (such as S. cerevisiae) and Pichia are examples of suitable yeast host cells, where suitable vectors have expression control sequences (such as promoters), origins of replication, termination sequences, and the like, as needed. Typical promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast is started from promoters including in particular alcohol dehydrogenase, isocytochrome C, and enzymes responsible for maltose and galactose utilization.

In addition to microorganisms, mammalian cells (e.g., mammalian cells cultured in in vitro cell cultures) can also be used to express and generate anti-Tau antibodies (e.g., polynucleotides encoding subject anti-Tau antibodies) of the invention. See Winnacker, From Genes to Clones, VCH Publishers, N.Y., N.Y. (1987). Suitable mammalian host cells include CHO cell lines, various Cos cell lines, HeLa cells, myeloma cell lines, and transformed B cells or hybridomas. Expression vectors for these cells may contain expression control sequences such as origin of replication, promoters and enhancers (Queen et al., Immunol. Rev. 89:49 (1986)), and necessary processing information sites such as ribosomes Binding sites, RNA splice sites, polyadenylation sites, and transcription terminator sequences. Examples of suitable expression control sequences are promoters derived from white immunoglobulin gene, SV40, adenovirus, bovine papilloma virus, cytomegalovirus and the like. See Co et al., J. Immunol. 148: 1149 (1992).

Once synthesized (chemically or recombinantly), the fibers of the present invention can be purified according to standard procedures in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, high performance liquid chromatography (HPLC), gel electrophoresis, etc. Lysogen. The plasminogen is substantially pure, such as at least about 80% to 85% pure, at least about 85% to 90% pure, at least about 90% to 95% pure, or 98% to 99% pure Or more pure, for example, free of contaminants such as cell debris, macromolecules other than the subject antibody, and the like.

Pharmaceutical formulation

Lyophilized formulations can be formed by mixing plasminogen with the desired purity with an optional pharmaceutical carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences, 16th Edition, Osol, A.ed. (1980)). Or aqueous solutions to prepare therapeutic formulations. Acceptable carriers, excipients, stabilizers are non-toxic to the recipient at the dosages and concentrations used, and include buffers such as phosphates, citrates, and other organic acids; antioxidants include ascorbic acid and methionine; and preservatives (such as Octadecyl dimethyl benzyl ammonium chloride; hexanediamine chloride; benzalconium chloride, benzethonium chloride; phenol, butanol or benzyl alcohol; alkyl parahydroxybenzoic acid Esters such as methyl or propyl parabens; catechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol); low molecular weight polypeptides (less than about 10 residues) ; Proteins such as serum albumin, gelatin or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, Disaccharides and other carbohydrates include glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, fucose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g. zinc-protein Complex); and / or non-ionic surfactants, such as TWEENTM , PLURONICSTM or polyethylene glycol (PEG). A preferred lyophilized anti-VEGF antibody formulation is described in WO 97/04801, which is incorporated herein by reference.

The formulations of the invention may also contain more than one active compound required for the particular condition to be treated, preferably those with complementary activities and no side effects with each other. For example, antihypertensive drugs, antiarrhythmic drugs, diabetes drugs, etc.

The plasminogen of the present invention can be encapsulated in microcapsules prepared by, for example, a coacervation technique or interfacial polymerization. And nanocapsules) or hydroxymethyl cellulose or gel-microcapsules and poly- (methyl methacrylate) microcapsules in coarse drops of emulsion. These techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

The plasminogen of the invention for in vivo administration must be sterile. This can be easily achieved by filtering through a sterilizing filter before or after freeze drying and reconstitution.

The plasminogen of the present invention can prepare a sustained-release preparation. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers having a certain shape and containing glycoproteins, such as membranes or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (such as poly (2-hydroxyethyl-methacrylate)) (Langer et al., J. Biomed. Mater. Res., 15: 167-277 (1981); Langer, Chem .Tech., 12: 98-105 (1982)) or poly (vinyl alcohol), polylactide (US Patent 3773919, EP 58,481), a copolymer of L-glutamic acid and γ ethyl-L-glutamic acid (Sidman, et al., Biopolymers 22: 547 (1983)), non-degradable ethylene-vinyl acetate (Langer, et al., Supra), or degradable lactic acid-glycolic acid copolymers such as Lupron DepotTM (injectable microspheres consisting of lactic-glycolic acid copolymer and leuprolide acetate), and poly D-(-)-3-hydroxybutyric acid. Polymers such as ethylene- Vinyl acetate and lactic-glycolic acid can continuously release molecules for more than 100 days, while some hydrogels release proteins for a short period of time. A reasonable strategy for protein stabilization can be designed based on related mechanisms. For example, if the mechanism of aggregation is found to be The formation of intermolecular SS bonds through the exchange of thiodisulfide bonds can be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling humidity, using Appropriate additives, and developing specific polymer matrix compositions stable. Administration and Dose

The administration of the pharmaceutical composition of the invention can be achieved in different ways, for example by intravenous, intraperitoneal, subcutaneous, intracranial, intrathecal, intraarterial (e.g. via carotid), intramuscular.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, or fixed oils. Intravenous vehicles contain fluid and nutritional supplements, electrolyte supplements, and so on. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases, and the like.

Medical personnel determine dosage regimens based on a variety of clinical factors. As is well known in the medical arts, the dosage of any patient depends on a number of factors, including the patient's size, body surface area, age, specific compound to be administered, gender, number and route of administration, overall health, and other drugs administered concurrently. The dosage range of the plasminogen-containing pharmaceutical composition of the present invention may be, for example, about 0.0001 to 2000 mg / kg, or about 0.001 to 500 mg / kg (for example, 0.02 mg / kg, 0.25 mg / kg, 0.5 mg / kg, 0.75 mg / kg, 10 mg / kg, 50 mg / kg, etc.) Subject weight. For example, the dose can be 1 mg / kg body weight or 50 mg / kg body weight or in the range of 1-50 mg / kg, or at least 1 mg / kg. Dosages above or below this exemplified range are also included, especially considering the factors described above. Intermediate doses in the above ranges are also included in the scope of the present invention. Subjects may administer such doses daily, every other day, every week, or according to any other schedule determined by empirical analysis. An exemplary dose schedule includes 1-10 mg / kg for consecutive days. There is a need for immediate assessment of treatment efficacy and safety during the administration of the drug of the invention.

Product or kit

One embodiment of the present invention relates to an article of manufacture or kit comprising a plasminogen or plasmin of the present invention that can be used to treat cardiovascular disease and related conditions caused by diabetes. The article preferably includes a container, label or packaging insert. Suitable containers are bottles, vials, syringes, etc. The container may be made of various materials such as glass or plastic. The container contains a composition that is effective in treating a disease or condition of the invention and has a sterile inlet (e.g., the container may be an intravenous solution pack or a vial containing a stopper pierceable by a hypodermic needle ). At least one active agent in the composition is plasminogen / plasmin. The label on or attached to the container indicates that the composition is used to treat the cardiovascular disease and its related conditions caused by diabetes according to the present invention. The preparation may further comprise a second container containing a pharmaceutically acceptable buffer, such as phosphate buffered saline, Ringer's solution, and glucose solution. It may further contain other substances required from a commercial and user standpoint, including other buffers, diluents, filters, needles and syringes. In addition, the article includes a package insert with instructions for use, including, for example, instructing a user of the composition to administer a plasminogen composition and other drugs to treat a concomitant disease to a patient.

Examples

Example 1 Plasminogen reduces renal fibrosis in 3% cholesterol hyperlipidemia model mice

Sixteen 9-week-old male C57 mice were fed a 3% cholesterol high-fat diet (Nantong Trofi) for 4 weeks to induce hyperlipidemia ^[30,31] . This model was designated as a 3% cholesterol hyperlipidemia model. Modeled mice continued to be fed a 3% cholesterol high-fat diet. Another 5 male C57 mice of the same week age were used as a blank control group and fed with ordinary maintenance feed during the experiment. Three days before the administration, 50 μL of blood was taken from each mouse, and total cholesterol was measured. The model mice were randomly divided into two groups based on the total cholesterol concentration and body weight. The plasminogen group and the vehicle PBS control group were used, 8 in each group. only. The first day of administration was recorded as the first day. Human plasminogen 1 mg / 0.1 ml / piece / day was injected into the tail vein of the plasminogen group, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. The mice were administered for 30 days after the administration on the 30th day, and the mice were sacrificed on the 31st day, and the kidneys were fixed in 4% paraformaldehyde for 24-48 hours. The fixed tissue was dehydrated with alcohol gradient and transparent with xylene before paraffin embedding. The section thickness was 3 μm. After dewaxing and rehydration, the sections were washed once, and stained with 0.1% Sirius Red saturated picric acid for 30 minutes, then rinsed with running water for 2 minutes, stained with hematoxylin for 1 minute, rinsed with running water, 1% hydrochloric acid alcohol, and ammonia was returned to blue. Rinse under running water, dry the neutral gum seal, and observe under a 200x optical microscope.

The results showed that the collagen deposition (marked by the arrow) of the kidney in the plasminogen-treated group (Figure 1C) was significantly less than that in the PBS-treated control group (Figure 1B), and the statistical difference was significant (Figure 1D); Chemical recovery has returned to normal levels (Figure 1A). This shows that plasminogen can effectively reduce renal fibrosis in 3% cholesterol hyperlipidemia model mice.

Example 2 Plasminogen Reduces 3% Cholesterol Hyperlipidemia Model Mouse Kidney Fat Deposition

Sixteen 9-week-old male C57 mice were fed a 3% cholesterol high-fat diet (Nantong Trofi) for 4 weeks to induce hyperlipidemia ^[30,31] . This model was designated as a 3% cholesterol hyperlipidemia model. Modeled mice continued to be fed a 3% cholesterol high-fat diet. Another 5 male C57 mice of the same week age were used as a blank control group and fed with ordinary maintenance feed during the experiment. Three days before the administration, 50 μL of blood was taken from each mouse, and total cholesterol was measured. The model mice were randomly divided into two groups based on the total cholesterol concentration and body weight. The plasminogen group and the vehicle PBS control group were used, 8 in each group. only. The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 30 days. The mice were sacrificed on the 31st day, and the kidneys were fixed in 4% paraformaldehyde for 24-48 hours, and they were settled in 15% and 30% sucrose at 4 ° C overnight, embedded in OCT, frozen sections 8 μm thick, and oil red O staining for 15 min , 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30 seconds, glycerin gelatin mounts. The sections were observed under a 400x optical microscope.

The results showed that the fat deposition (marked by the arrow) in the kidney of the plasminogen-treated group (Fig. 2C) mice was significantly less than that in the PBS-administered control group (Fig. 2B), and the statistical analysis was significantly different (Fig. 2D). The level of lipid deposition in the lysogen group was similar to that in the blank control group (Figure 2A). This shows that plasminogen can reduce the deposition of fat in the kidneys of hyperlipidemia model mice, thereby reducing the kidney damage caused by fat deposition.

Example 3 Plasminogen reduces fat deposition in the liver of a 16-week hyperlipidemia model mouse

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. The mice were sacrificed for 30 days, and the mice were sacrificed on the 31st day. The livers were fixed in 4% paraformaldehyde for 24-48 hours, and they were settled in 15% and 30% sucrose at 4 ° C overnight, embedded in OCT, and frozen in sections. 8μm, oil red O staining for 15min, 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30s, glycerin gelatin mounts. The sections were observed under a 200x optical microscope.

Oil Red O staining can show lipid deposition, reflecting the extent of lipid deposition ^[32] . The results showed that liver fat deposition in the plasminogen-administered group (Fig. 3B) was significantly less than that in the PBS-administered control group (Fig. 3A), and the statistical analysis of the quantitative difference was significant (Fig. 3C). This shows that plasminogen can reduce fat deposition in the liver of hyperlipidemia model mice.

Example 4 Plasminogen reduces lipid deposition in the aortic sinus of a 16-week hyperlipidemia model mouse

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. The mice were sacrificed for 30 days, and the mice were sacrificed on the 31st day. Heart tissues were fixed in 4% paraformaldehyde for 24-48 hours, and they were settled in 15% and 30% sucrose at 4 ° C overnight. Frozen sinus sections were 8 μm thick, oil red O stained for 15 min, 75% alcohol differentiated for 5 seconds, hematoxylin stained for 30 s, and glycerin gelatin was mounted on slides. The sections were observed under an optical microscope at 40 (Fig. 4A, 4B) and 200 (Fig. 4C, 4D) times.

The results showed that the aortic sinus fat deposition of the mice given the plasminogen group (Fig. 4B, 4D) was significantly less than that of the vehicle-administered PBS control group (Fig. 4A, 4C), and the statistical difference was significant (Fig. 4E). This shows that plasminogen can reduce lipid deposition in the aortic sinus of hyperlipidemia model mice.

Example 5 Plasminogen ameliorates aortic sinus injury in 16-week hyperlipidemia model mice

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. The mice were administered for 30 days, and the mice were sacrificed on the 31st day. Heart tissues were taken and fixed in 4% paraformaldehyde for 24-48 hours. The fixed tissue was dehydrated with alcohol gradient and transparent with xylene before paraffin embedding. The fixed tissue samples were paraffin-embedded after dehydration with alcohol gradient and transparent xylene. Aortic sinus tissue sections were 3 μm thick. The sections were dewaxed and rehydrated and stained with hematoxylin and eosin (HE staining). After 1% hydrochloric acid alcohol differentiation, the ammonia water returned to blue and the alcohol gradient was dehydrated. B), 200 times (Fig. 5C, D) observation under an optical microscope.

The results showed that the PBS control group (Figure 5A, C) gave foam cells (indicated by arrows) on the inner wall of the aortic sinus, and the plaque deposition was heavy; the plasminogen group (Figure 5B, D) gave the inner wall of the aortic sinus Only slight foam cell deposition was observed, and no obvious atheromatous plaque deposition was found under the intima. The aortic sinus inner wall in the plasminogen group had less damage. This shows that plasminogen can improve the inner wall damage of arterial sinus in hyperlipidemia model mice.

Example 6 Plasminogen reduces heart fibrin expression in 16-week hyperlipidemia model mice

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. The mice were administered for 30 days, and the mice were sacrificed on the 31st day. Heart tissues were taken and fixed in 4% paraformaldehyde for 24-48 hours. The fixed tissue was dehydrated with alcohol gradient and transparent with xylene before paraffin embedding. The thickness of the tissue section was 3 μm. The sections were washed with water after dewaxing and rehydration. Incubate with 3% hydrogen peroxide for 15 minutes, and wash twice with 5 minutes each time. 5% normal sheep serum (Vector laboratories, Inc., USA) was blocked for 30 minutes; after the time was up, the sheep serum was discarded and the tissue was circled with a PAP pen. Incubate with 3% hydrogen peroxide for 15 minutes, and wash twice with 5 minutes each time. Rabbit anti-mouse fibrin antibody (Abcam) was incubated at 4 ° C overnight and washed twice with 0.01 MPBS for 5 minutes each. Goat anti-rabbit IgG (HRP) antibody (Abcam) secondary antibody was incubated for 1 hour at room temperature and washed twice with PBS for 5 minutes each. The color was developed according to DAB kit (Vector laboratories, Inc., USA). After washing with water 3 times, hematoxylin was counterstained for 30 seconds, and washed with running water for 5 minutes. Gradient alcohol dehydration, xylene transparent and neutral gum seals, sections were observed under a 200x optical microscope. Fibrinogen is a precursor of fibrin. In the presence of tissue damage, as a stress response of the body to the damage, fibrinogen is hydrolyzed into fibrin and deposited at the site of the damage ^[33,34] . Therefore, the level of fibrin at the injury site can be used as an indicator of the degree of injury.

The immunohistochemical staining results showed that the positive expression of cardiac fibrin in the plasminogen-treated mice (Figure 6B) was significantly less than that in the vehicle-treated PBS control group (Figure 6A), and the statistical difference was significant (Figure 6C), indicating that fibrinolysis Enzymes can reduce myocardial damage caused by hyperlipidemia.

Example 7 Plasminogen effectively protects myocardial injury in 16-week hyperlipidemia model mice

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. The mice were administered for 30 days, and the mice were sacrificed on the 31st day. Heart tissues were taken and fixed in 4% paraformaldehyde for 24-48 hours. The fixed tissue was dehydrated with alcohol gradient and transparent with xylene before paraffin embedding. The thickness of the tissue section was 3 μm. The sections were washed with water after dewaxing and rehydration. Incubate with 3% hydrogen peroxide for 15 minutes, and wash twice with 5 minutes each time. 5% normal sheep serum (Vector laboratories, Inc., USA) was blocked for 30 minutes; after the time was up, the sheep serum was discarded and the tissue was circled with a PAP pen. Incubate with 3% hydrogen peroxide for 15 minutes, and wash twice with 5 minutes each time. Goat anti-mouse IgM (HRP) antibody (Abcam) was incubated for 1 hour at room temperature and washed twice with PBS for 5 minutes each. The color was developed according to DAB kit (Vector laboratories, Inc., USA). After washing with water 3 times, hematoxylin was stained for 30 seconds, and then washed with running water for 5 minutes. Gradient alcohol dehydration, xylene transparent, neutral gum seals, sections were observed under a 200x optical microscope.

IgM antibodies play an important role in removing apoptotic and necrotic cells. The level of local IgM antibodies in damaged tissues and organs is positively correlated with the degree of damage ^[35,36] . Therefore, the level of local IgM antibodies in tissues and organs can reflect the degree of damage to the tissues and organs.

Immunostaining results showed that the positive expression of IgM in the heart of the plasminogen-treated mice (Figure 7B) was significantly less than that in the vehicle-treated PBS control group (Figure 7A), indicating that plasminogen can reduce the heart of the hyperlipidemia model animals. damage.

Example 8 Plasminogen reduces cardiac fibrosis in 16-week hyperlipidemia model mice

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. The mice were administered for 30 days, and the mice were sacrificed on the 31st day. Heart tissues were taken and fixed in 4% paraformaldehyde for 24-48 hours. The fixed tissue was dehydrated with alcohol gradient and transparent with xylene before paraffin embedding. The thickness of the tissue sections is 3 μm. After dewaxing and rehydration, the sections are washed once, and stained with 0.1% Sirius Red saturated picric acid for 30 minutes, then rinsed with running water for 2 minutes, hematoxylin stained for 1 minute, rinsed with running water, 1% hydrochloric acid alcohol, and ammonia water returns to blue. After washing with running water, the neutral gum seal sheet was dried and observed under a 200x optical microscope.

Sirius red staining can make collagen lastingly stained. As a special staining method for pathological sections, Sirius red staining can specifically show collagen tissue.

The staining results showed that collagen deposition in the plasminogen-treated group (Figure 8B) was significantly less than that in the vehicle-treated PBS control group (Figure 8A), indicating that plasminogen can reduce collagen deposition in the heart tissue of mice with hyperlipidemia. And reduce myocardial fibrosis.

Example 9 Plasminogen repairs myocardial injury in a 16-week hyperlipidemia model mouse

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. After 30 days of administration, the mice started fasting on the 30th day and fasted for 16 hours. On the 31st day, the eyeballs were taken for blood collection, and the supernatant was obtained by centrifugation. Cardiac troponin I (CTNI) detection kit was used. (Nanjing Jiancheng) Detection of troponin in serum.

Cardiac troponin I is an important marker of myocardial injury, and its serum concentration can reflect the degree of myocardial injury ^[37] .

The test results showed that the concentration of serum cardiac troponin in the vehicle-administered PBS control group was significantly higher than that in the plasminogen-administered group, and the statistical difference was significant (Figure 9). This shows that plasminogen can significantly improve the heart injury in mice with hyperlipidemia.

Example 10 Plasminogen Increases High Density Lipoprotein Cholesterol Concentration in Serum of 3% Cholesterol Hyperlipidemic Model Mice

Sixteen 9-week-old male C57 mice were fed a 3% cholesterol high-fat diet (Nantong Trofi) for 4 weeks to induce hyperlipidemia ^[30,31] . This model was designated as a 3% cholesterol hyperlipidemia model. Modeled mice continued to be fed a 3% cholesterol high-fat diet. Three days before the administration, 50 μL of blood was taken from each mouse, and total cholesterol was measured, and randomly divided into two groups according to the total cholesterol concentration and weight, with 8 mice in each group. The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 20 days. The mice were fasted for 16 hours on the 10th and 20th days, and 50 μl of blood was taken from the orbital venous plexus on the 11th and 21st days, and the supernatant was obtained by centrifugation to detect serum high-density lipoprotein cholesterol (HDL-C). The high-density lipoprotein cholesterol content in this article was detected by the method described in the detection kit (Nanjing Jiancheng Biotechnology Research Institute, Cat. No. A112-1).

High-density lipoprotein is an anti-atherosclerotic plasma lipoprotein, which is a protective factor for coronary heart disease. It is commonly known as "vascular scavenger".

The test results showed that the serum HDL-C concentration of the plasminogen-treated mice was significantly higher than that of the vehicle-administered PBS control group, and the HDL-C concentrations of the two groups were statistically different after 10 and 20 days of administration (Figure 10). . This shows that plasminogen can increase the content of high-density lipoprotein cholesterol in the serum of hyperlipidemia model mice, and improve blood lipid disorders in hyperlipidemia mice.

Example 11 Plasminogen Reduces 3% Cholesterol Hyperlipidemia Model Mouse Serum Total Cholesterol Level

Sixteen 9-week-old male C57 mice were fed a 3% cholesterol high-fat diet (Nantong Trofi) for 4 weeks to induce hyperlipidemia ^[30,31] . This model was designated as a 3% cholesterol hyperlipidemia model. Modeled mice continued to be fed a 3% cholesterol high-fat diet. Three days before the administration, 50 μL of blood was taken from each mouse, and total cholesterol was measured, and randomly divided into two groups according to the total cholesterol concentration and weight, with 8 mice in each group. The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 20 days. On the 20th day, the mice were fasted for 16 hours, and on the 21st day, 50 μL of blood was taken from the orbital venous plexus, and the supernatant was obtained by centrifugation. The total cholesterol test kit (Nanjing Jiancheng Institute of Biological Engineering, Cat. .

The test results showed that the total cholesterol concentration of the mice given the plasminogen group was significantly lower than that of the vehicle given the PBS control group, and the statistical difference was significant (Figure 11). This shows that plasminogen can reduce the total cholesterol content in the serum of hyperlipidemia model mice.

Example 12 Plasminogen lowers the level of serum low-density lipoprotein cholesterol in a mouse model of 3% cholesterol hyperlipidemia

Sixteen 9-week-old male C57 mice were fed a 3% cholesterol high-fat diet (Nantong Trofi) for 4 weeks to induce hyperlipidemia ^[30,31] . This model was designated as a 3% cholesterol hyperlipidemia model. Modeled mice continued to be fed a 3% cholesterol high-fat diet. Three days before the administration, 50 μl of blood was taken from each mouse, and total cholesterol was measured, and randomly divided into two groups according to the total cholesterol concentration and body weight, 8 mice in each group. The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 20 days. The mice were fasted for 16 hours on the 20th day, and 50 μL of blood was taken from the orbital venous plexus on the 21st day, and the supernatant was obtained by centrifugation. Low-density lipoprotein cholesterol (LDL-C) detection.

Low density lipoprotein is a kind of lipoprotein particles that carry cholesterol into peripheral tissue cells. It can be oxidized to oxidized low density lipoprotein. When low density lipoprotein, especially oxidatively modified low density lipoprotein (OX-LDL), is in excess, The cholesterol it carries accumulates on the walls of the arteries, causing arteriosclerosis. Therefore LDL cholesterol is called "bad cholesterol".

The results showed that the concentration of mice (LDL-C) in the plasminogen-administered group was significantly lower than that in the vehicle-administered PBS control group, and the statistical difference was significant (Figure 12). This shows that plasminogen can reduce the content of low-density lipoprotein cholesterol in the serum of hyperlipidemia model mice, and improve blood lipid disorders in hyperlipidemia mice.

Example 13 Plasminogen reduces the risk of atherosclerosis in 3% cholesterol hyperlipidemia model mice

Sixteen 9-week-old male C57 mice were fed a 3% cholesterol high-fat diet (Nantong Trofi) for 4 weeks to induce hyperlipidemia ^[30,31] . This model was designated as a 3% cholesterol hyperlipidemia model. Modeled mice continued to be fed a 3% cholesterol high-fat diet. Three days before the administration, 50 μl of blood was taken from each mouse, and total cholesterol (T-CHO) was measured, and randomly divided into two groups according to the total cholesterol concentration and body weight, each group containing 8 rats. The first day of administration was recorded as the first day. Human plasminogen 1 mg / 0.1 ml / piece / day was injected into the tail vein of the plasminogen group, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. On the 20th day, the mice started fasting for 16 hours. On the 21st day, 50 μL of blood was taken from the orbital venous plexus, and the supernatant was obtained by centrifugation. The total cholesterol content was measured using a total cholesterol test kit (Nanjing Jiancheng Biotechnology Research Institute). , Article number A111-1) for detection; high-density lipoprotein cholesterol (HDL-C) content was detected using a high-density lipoprotein cholesterol detection kit (Nanjing Jiancheng Biotechnology Research Institute, article number A112-1).

The atherosclerosis index is a comprehensive indicator for clinically predicting atherosclerosis. It is believed that it is more clinically significant than the individual total cholesterol, triglyceride, high-density lipoprotein, and low-density lipid in estimating the risk of coronary heart disease. Larger protein ^[38] . Atherosclerosis Index = (T-CHO-HDL-C) / HDL-C.

The calculation results showed that the atherosclerosis index of the plasminogen-administered group was significantly lower than that of the vehicle-administered PBS control group, and the statistical difference was significant (Figure 13). This shows that plasminogen can reduce the risk of atherosclerosis in hyperlipidemia model mice.

Example 14 Plasminogen Reduces the Risk of Heart Attack in 3% Cholesterol Hyperlipidemia Model Mice

Sixteen 9-week-old male C57 mice were fed a 3% cholesterol high-fat diet (Nantong Trofi) for 4 weeks to induce hyperlipidemia ^[30,31] . This model was designated as a 3% cholesterol hyperlipidemia model. Modeled mice continued to be fed a 3% cholesterol high-fat diet. Three days before the administration, 50 μl of blood was taken from each mouse, and the total cholesterol (T-CHO) was measured, and randomly divided into two groups according to the total cholesterol concentration, 8 mice in each group. The first day of administration was recorded as the first day. Human plasminogen 1 mg / 0.1 ml / piece / day was injected into the tail vein of the plasminogen group, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. On the 20th day, the mice started fasting for 16 hours. On the 21st day, 50 μL of blood was taken from the orbital venous plexus, and the supernatant was obtained by centrifugation. The total cholesterol content was measured using a total cholesterol test kit (Nanjing Jiancheng Biotechnology Research Institute). , Article number A111-1) for detection; high-density lipoprotein cholesterol (HDL-C) content was detected using a high-density lipoprotein cholesterol detection kit (Nanjing Jiancheng Biotechnology Research Institute, article number A112-1). Cardiac risk index = T-CHO / HDL-C.

The cardiac risk index (CRI) is used to assess the risk of dyslipidemia-induced heart disease ^[38] .

The results showed that the CRI of the plasminogen-administered group was significantly smaller than that of the vehicle-administered PBS control group, and the statistical difference was extremely significant (Figure 14). This shows that plasminogen can effectively reduce the risk of heart disease in hyperlipidemia model mice.

Example 15 Plasminogen improves liver lipid deposition in diabetic mice

Ten 24-25 week-old male db / db mice were randomly divided into two groups, the vehicle was given the PBS control group and the plasminogen group was given five each. The day of the experiment was recorded as day 0 and weighed into groups, and plasminogen or PBS was given on day 1. Plasminogen was injected into the plasminogen group at a dose of 2 mg / 0.2ml / head / day, and the same volume of PBS was injected into the PBS control group through the tail vein for 35 consecutive days. Mice were sacrificed on day 36. Liver tissues were fixed with 4% paraformaldehyde for 24-48 hours, and they were settled in 15% and 30% sucrose at 4 ° C overnight, embedded in OCT, frozen sections were 8 μm thick, and oil red O stained for 15 min. , 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30 seconds, glycerin gelatin mounts. The sections were observed under a 400x optical microscope.

The staining results showed that the area of lipid deposition in the liver of mice given the plasminogen group (Fig. 15B) was significantly smaller than that in the vehicle-administered PBS control group (Fig. 15A), and the statistical difference was significant (P = 0.02) (Fig. 15C). This shows that plasminogen can reduce the deposition of fat in the liver of diabetic mice.

Example 16 Plasminogen Reduces Aortic Wall Damage in Diabetic Mice

Ten 24-25 week-old male db / db mice were randomly divided into two groups, each with PBS control group and 5 plasminogen group. The day of the experiment was recorded as the weighing group on day 0, and PBS or plasminogen was given on the first day for 31 consecutive days. Plasminogen was injected into the plasminogen group at a dose of 2 mg / 0.2ml / head / day, and the same volume of PBS was injected into the PBS control group. Mice were sacrificed on day 32 and the aorta was fixed in 10% neutral formalin fixative for 24 hours. The fixed aorta was dehydrated with alcohol gradient and cleared with xylene before paraffin embedding. The thickness of the tissue sections was 5 μm. The sections were dewaxed and rehydrated and stained with hematoxylin and eosin (HE staining). After the 1% hydrochloric acid alcohol differentiation, the ammonia water returned to blue and the alcohol gradient dehydrated the slides. Observe under an optical microscope and a 1000x (Figure 16C, D) oil microscope.

Diabetes combined with hyperlipidemia is a more common complication of diabetes and an important risk factor for diabetic macroangiopathy ^[39] .

The staining results showed that foamed cells were deposited on the vessel wall of the PBS control group (Fig. 16A, C) (arrow marks), the middle elastic membrane was disorderly arranged, the vessel wall was thickened, and the wall was uneven; the plasminogen group (Figures 16B, D) The structure of the middle elastic membrane is regular, wavy, and the thickness of the vessel wall is uniform. It is shown that the injection of plasminogen can reduce the lipid deposition in the aortic wall of diabetic mice and has a certain protective effect on the damage caused by the lipid deposition in the arterial wall.

Example 17 Plasminogen reduces ventricular lipid deposition in diabetic mice

Nine 26-week-old male db / db mice were randomly divided into groups, 4 were given the plasminogen group, and 5 were given the vehicle PBS control group. Human plasminogen 2mg / 0.2ml / piece / day was injected into the plasminogen group through the tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group for 35 days. Mice were sacrificed on day 36. Hearts were fixed in 4% paraformaldehyde for 24-48 hours, and they were settled in 15% and 30% sucrose at 4 ° C overnight, embedded in OCT, frozen sections 8 μm thick, oil red O stain 15min, 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30 seconds, glycerol gelatin seals. The sections were observed under a 200x optical microscope.

The results showed that the plasminogen-administered mice (Fig. 17B) had significantly less ventricular lipid deposition (indicated by arrows) than the vehicle-administered PBS control group (Fig. 17A). This shows that plasminogen can reduce the deposition of fat in the ventricle of diabetic mice and promote the repair of ventricular damage.

Example 18 Plasminogen Increases High-density Lipoprotein Cholesterol Levels in Serum of Diabetic Mice

Twenty 26-week-old male db / db mice were randomly divided into groups, 11 were given the plasminogen group, and 9 were each given the vehicle PBS control group. The day of the experiment was recorded as day 0 and weighed into groups. On day 1, plasminogen or PBS was administered for 35 consecutive days. Human plasminogen 2mg / 0.2ml / piece / day was injected into the plasminogen group through the tail vein, and the same volume of PBS was injected into the control group through the tail vein. On the 36th day, whole blood was collected from the eyeballs of the mice, centrifuged at 3500r / min for 10 minutes at 4 ° C, and the supernatant was collected and tested for high density in serum using a high-density lipoprotein detection kit (Nanjing Jiancheng Biotechnology Research Institute, Cat. No. A112-1). Lipoprotein cholesterol (HDL-C) concentration.

The test results showed that the content of HDL-C in the serum of mice given the plasminogen group was higher than that in the vehicle given the PBS control group, and the statistical difference was significant (Figure 18). This indicates that plasminogen injection can promote the increase of serum high-density lipoprotein cholesterol and improve the diabetic dyslipidemia.

Example 19 Plasminogen Reduces Low Density Lipoprotein Cholesterol in Serum of Diabetic Mice

Ten 24-25 week-old male db / db mice were randomly divided into groups, each of which was given a plasminogen group and a vehicle PBS control group, and 3 db / m mice were taken as normal control groups. The day of the experiment was recorded as the weighing group on day 0, and plasminogen or PBS was given on the first day for 31 consecutive days. Human plasminogen 2mg / 0.2ml / piece / day was injected into the plasminogen group through the tail vein. The same volume of PBS was injected into the tail vein of the PBS control group. The mice in the normal control group were not treated. On day 32, the whole blood was collected from the eyeballs of the mice, centrifuged at 3500r / min for 10 minutes at 4 ° C, and the supernatant was taken and the serum was detected using a low-density lipoprotein cholesterol detection kit (Nanjing Jiancheng Biotechnology Research Institute, article number A113-1). Low density lipoprotein cholesterol (LDL-C) concentration.

The results showed that after 31 days of continuous injection of human-derived plasmin source in diabetic model mice, the serum LDL-C content in the plasminogen-treated mice was lower than that in the PBS control group, and the statistical difference was close to significant (P = 0.1) (Figure 19). This shows that plasminogen can reduce the content of LDL-C in serum.

Example 20 Plasminogen Reduces Total Cholesterol Content in Serum of ApoE Atherosclerotic Mice

Thirteen 6-week-old male ApoE mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, TP2031) for 16 weeks to induce an atherosclerotic model ^[40,41] . Modeled mice continued to be fed a high-fat, high-cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to detect the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 7 were given to the PBS control group, and 6 were given to the plasminogen group. . The first day of administration was set as the first day. Human plasminogen was injected into the tail vein of the plasminogen group at a dose of 1 mg / 0.1ml / piece / day, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 30 days. The mice were fasted for 16 hours on the 30th day, blood was removed from the eyeballs on the 31st day, and the supernatant was obtained by centrifugation using a total cholesterol test kit (Nanjing Jiancheng Biotechnology Research Institute, article number A111-1) for total cholesterol detection.

The test results showed that the total cholesterol concentration of the mice given the plasminogen group was significantly lower than that of the PBS control group, and the statistical difference was significant (P = 0.014) (Figure 20). This shows that plasminogen can reduce the total cholesterol content in the serum of ApoE atherosclerosis model mice, and improve atherosclerotic dyslipidemia.

Example 21 Plasminogen Reduces Serum Triglyceride Content in ApoE Atherosclerotic Mice

Thirteen 6-week-old male ApoE mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, TP2031) for 16 weeks to induce an atherosclerotic model ^[40,41] . Modeled mice continued to be fed a high-fat, high-cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to detect the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 7 were given to the PBS control group, and 6 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 30 days. The mice were fasted for 16 hours on the 30th day, and the eyeballs were collected on the 31st day, and the supernatant was obtained by centrifugation. The triglyceride detection kit (Nanjing Jiancheng Biotechnology Research Institute, article number A110-1) was used for triglyceride detection.

The test results showed that the triglyceride concentration in the plasminogen-treated mice was significantly lower than that in the PBS control group, and the statistical difference was significant (P = 0.013) (Figure 21). This shows that plasminogen can reduce the triglyceride content in the serum of ApoE atherosclerosis model mice and improve atherosclerotic dyslipidemia.

Example 22 Plasminogen reduces the content of low density lipoprotein cholesterol in serum of ApoE atherosclerotic mice

Thirteen 6-week-old male ApoE mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, TP2031) for 16 weeks to induce an atherosclerotic model ^[40,41] . Modeled mice continued to be fed a high-fat, high-cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to detect the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 7 were given to the PBS control group, and 6 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 30 days. The mice were fasted for 16 hours on the 30th day, and the eyeballs were collected on the 31st day, and the supernatant was obtained by centrifugation using a low-density lipoprotein cholesterol (LDL-C) detection kit (Nanjing Jiancheng Biotechnology Research Institute, article number A113-1). LDL-C detection.

The results showed that the concentration of LDL-C in the plasminogen-administered group was significantly lower than that in the PBS-administered control group, and the statistical difference was significant (P = 0.017) (Figure 22). This shows that plasminogen can reduce the low-density lipoprotein cholesterol content in the serum of ApoE atherosclerotic model mice, and improve blood lipid disorders in atherosclerotic model mice.

Example 23 Plasminogen improves liver lipid deposition in ApoE atherosclerotic mice

Thirteen 6-week-old male ApoE mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, TP2031) for 16 weeks to induce an atherosclerotic model ^[40,41] . Modeled mice continued to be fed a high-fat, high-cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to detect the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 7 were given to the PBS control group, and 6 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 30 days. Mice were sacrificed on day 31. Liver tissues were collected and fixed in 4% paraformaldehyde for 24-48 hours. They were allowed to sink to the bottom in 15% and 30% sucrose at 4 ° C overnight, embedded in OCT, frozen sections were 8 μm thick, oil red O. Stained for 15 min, differentiated with 75% alcohol for 5 seconds, hematoxylin stained for 30 seconds, and mounted on glycerin gelatin. The sections were observed under a 400x optical microscope.

The staining results showed that liver fat deposition in the plasminogen-treated group (Fig. 23B) was significantly less than that in the vehicle-administered PBS control group (Fig. 23A), and the statistical analysis was significantly different (P = 0.02) (Fig. 23C). This shows that plasminogen can reduce the deposition of fat in the liver of atherosclerotic model mice.

Example 24 Plasminogen improves lipid deposition in aortic sinuses of ApoE atherosclerotic mice

Thirteen 6-week-old male ApoE mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, TP2031) for 16 weeks to induce an atherosclerotic model ^[40,41] . Modeled mice continued to be fed a high-fat, high-cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to detect the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 7 were given to the PBS control group, and 6 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the tail vein of the plasminogen group mice, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. 30 days. Mice were sacrificed on day 31. Heart tissues were fixed in 4% paraformaldehyde for 24-48 hours, and they were settled in 15% and 30% sucrose at 4 ° C overnight, embedded in OCT, frozen sections 8 μm thick, oil red O Stained for 15min, differentiated with 75% alcohol for 5 seconds, stained with hematoxylin for 30s, and mounted on glycerin gelatin. The sections were observed under a 40x optical microscope.

The staining results showed that the aortic sinus fat deposition of the mice given the plasminogen group (Fig. 24B) was significantly less than that of the vehicle-administered PBS control group (Fig. 24A). This shows that plasminogen can reduce lipid deposition in the aortic sinus of atherosclerotic model mice.

Example 25 Plasminogen reduces aortic sinus fibrosis in 16-week hyperlipidemia model mice

Eleven 6-week-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, Cat. No. TP2031) for 16 weeks to induce a hyperlipidemia model ^[30,31] , and this model was designated as 16-week hyperlipidemia model. Modeled mice continued to be fed a high cholesterol diet. Three days before the administration, 50 μl of blood was taken from each to measure the total cholesterol (T-CHO) content, and randomly divided into two groups based on the T-CHO content, 6 were given to the PBS control group, and 5 were given to the plasminogen group. . The first day of administration was recorded as the first day. Human plasminogen 1mg / 0.1ml / piece / day was injected into the plasminogen group tail vein, and the same volume of PBS was injected into the tail vein of the vehicle PBS control group. After 30 days of administration, the mice were sacrificed on the 31st day, and the hearts were taken and fixed in 4% paraformaldehyde for 24-48 hours. The fixed tissue was dehydrated with alcohol gradient and transparent with xylene before paraffin embedding. The thickness of the aortic sinus section is 3 μm. After dewaxing and rehydration, the sections are washed once, stained with 0.1% Sirius Red saturated picric acid for 30 minutes, washed with running water for 2 minutes, hematoxylin stained for 1 minute, washed with running water, 1% hydrochloric acid alcohol, ammonia water. Return to blue, rinse with running water, dry the neutral gum seal sheet, and observe under 40 (Figure 25A, 25B), 200 times (Figure 25C, 25D) optical microscope.

The results showed that the area of collagen deposition (arrows) on the inner wall of the aortic sinus vessels in the plasminogen group (Figure 25B, 25D) was significantly smaller than that in the PBS control group (Figure 25A, 25C), indicating that plasminogen could Subtracting Aortic Sinus Fibrosis in Mice with Hyperlipidemia.

Example 26 Plasminogen Improves Compensatory Hypertrophy of ApoE Atherosclerotic Mouse Heart

Thirteen 6-week-old male ApoE mice were fed a high-fat, high-cholesterol diet (Nantong Trofi, TP2031) for 16 weeks to induce an atherosclerotic model ^[40,41] . 50 μl of blood was collected from each mouse three days before the administration to determine the total cholesterol (T-CHO) content. The mice were randomly divided into two groups according to the T-CHO content. 6 lysogen groups. On the first day of administration, the mice in the plasminogen group were injected with human-derived plasminogen 1 mg / 0.1 mL / piece / day in the tail vein, and the same volume of PBS was injected in the tail vein of the vehicle PBS control group. After 30 days of administration, high-fat and high-cholesterol feed was continued during the administration. The mice were sacrificed on the 31st day after administration, and the heart was weighed and the heart coefficient was calculated. Cardiac coefficient (%) = heart weight / body weight × 100.

The results showed that the heart coefficient of the plasminogen-administered mice was significantly lower than that of the vehicle-administered PBS control group (Figure 26). It indicated that plasminogen can reduce the compensatory hypertrophy of the heart caused by heart injury in ApoE atherosclerosis model mice.

references

[1] Zhao Kejian, editor. Handbook of modern pharmaceutical terminology. Beijing: China Medical Science and Technology Press. 2004. p. 533

[2] Shafrir E., Raz. I. Diabetes: Mellitus or Lipidus [J]. Diabetologia, 2003, 46: 433-440.

[3] Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: Current management guidelines [J]. Arch Intern Med. 2003, 163: 33-40.

[4] Appel G. Lipid adnormalities in renal disease [J]. Kidney Int, 1991, 39: 169.

[5] J Zah, Kov, H Varerkov, et al., Dislipoproteinemia and Chronic Kidney Failure [J]. Vnitr Lek. 2000, 46 (9): 539-46.

[6] Effat Razeghi, Mohammadreza Shafipour et al. Lipid Disturbances Before and After Renal Transplant. Effat Razeghi et al / Experimental and Clinical Transplantation (2011) 4: 230-235

[7] Grone HJ. Glomerular lipids in non-hereditary forms of glomerulopathy / glomerulo nephritis [J]. Nephrol. Dial Transplant. 1999, 14: 1595-1598.

[8] Larking RC. Dunlop ME, The link between hyperglycaemia and diabetic nephropathy [J] Athrosclerosis, 2001, 156 (2): 25-33.

[9] Alexander CM and Werb, Z. (1991). Extracellular matrix degradation. In Cell Biology of Extracellular Matrix, Hay ED, ed. (New York: Plenum Press), pp. 255-302.

[10] Werb, Z., Mainardi, CL, Vater, CA, and Harris, ED, Jr. (1977). Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N. Engl. J Med. 296 , 1017-1023.

[11] He, CS, Wilhelm, SM, Pentland, AP, Marmer, BL, Grant, GA, Eisen, AZ, and Goldberg, GI (1989). Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. US A 86 , 2632-2636.

[12] Stoppelli, MP, Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, RK (1985). Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. US A 82 , 4939-4943.

[13] Vassalli, JD, Baccino, D., and Belin, D. (1985). A cellular binding site for the Mr 55, 000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100 , 86-92 .

[14] Wiman, B. and Wallen, P. (1975). Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography. Eur. J Biochem. 50 , 489-494.

[15] Saksela, O. and Rifkin, DB (1988). Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. 4 , 93-126.

[16] Raum, D., Marcus, D., Alper, CA, Levey, R., Taylor, PD, and Starzl, TE (1980). Synthesis of human plasminogen by the liver. Science 208 , 1036-1037.

[17] Wallén P (1980). Biochemistry of plasminogen. In Fibrinolysis, Kline DL and Reddy KKN, eds. (Florida: CRC)

[18] Sottrup-Jensen, L., Zajdel, M., Claeys, H., Petersen, TE, and Magnusson, S. (1975). Amino-acid sequence of activation cleavage site in plasminogen: homology with "pro" part of prothrombin. Proc. Natl. Acad. Sci. US A 72 , 2577-2581.

[19] Collen, D. and Lijnen, HR (1991). Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78 , 3114-3124.

[20] Alexander, CM and Werb, Z. (1989). Proteinases and extracellular matrix remodeling. Curr. Opin. Cell Biol. 1 , 974-982.

[21] Mignatti, P. and Rifkin, DB (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 73 , 161-195.

[22] Collen, D. (2001). Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology. (Am. Soc. Hematol. Educ. Program.) 1-9.

[23] Rifkin, DB, Moscatelli, D., Bizik, J., Quarto, N., Blei, F., Dennis, P., Flaumenhaft, R., and Mignatti, P. (1990). Growth factor control of extracellular proteolysis. Cell Differ. Dev. 32 , 313-318.

[24] Andreasen, PA, Kjoller, L., Christensen, L., and Duffy, MJ (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72 , 1-22.

[25] Rifkin, DB, Mazzieri, R., Munger, JS, Noguera, I., and Sung, J. (1999). Proteolytic control of growth factor availability. APMIS 107 , 80-85.

[26] Marder V J, Novokhatny V. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential [J]. Journal of Thrombosis and Haemostasis, 2010, 8 (3): 433-444.

[27] Hunt JA, Petteway Jr SR, Scuderi P, et al. Simplified recombinant plasmin: production and fu-nctional comparison of a novel thrombolytic molecule with plasma-derived plasmin [J]. Thromb Haemost, 2008, 100 (3): 413-419.

[28] Sottrup-Jensen L, Claeys H, Zajdel M, et al. The primary structure of human plasminogen: Isolation of two lysine-binding fragments and one “mini” -plasminogen (MW, 38, 000) by elastase-catalyzed- specific limited proteolysis [J]. Progress in chemical fibrinolysis and thrombolysis, 1978, 3: 191-209.

[29] Nagai N, Demarsin E, Van Hoef B, et al. Recombinant human microplasmin: production and potential therapeutic properties [J]. Journal of Thrombosis and Haemostasis, 2003, 1 (2): 307-313.

[30] Dominika Nackiewicz, Paromita Dey, Barbara Szczerba et al. Inhibitor of differentiation 3, a transcription factor regulates hyperlipidemia associated kidney disease. Nephron Exp Nephrol. 2014; 126 (3): 141-147.

[31] Ming Gu1, Yu Zhang., Shengjie Fan et al. Extracts of Rhizoma Polygonati Odorati Prevent High-Fat Diet-Induced Metabolic Disorders in C57BL / 6 Mice. PLoS ONE 8 (11): e81724.

[32] Siobhan M. Craige, PhD, Shashi Kant et al. Endothelial NADPH oxidase 4 protects ApoE-/-mice from atherosclerotic lesions. Free Radic Biol Med. 2015 December; 89: 1-7.

[33] Dimitrios Davalos, Katerina Akassoglou. Fibrinogen as a key regulator of inflammation in disease. Seminars in Immunopathology, 2012. 34 (1): 43-62.

[34] Valvi D, Mannino DM, Mullerova H, et al. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis2012; 7: 173-82.

[35] Zhang M, Takahashi K, Alicot EM, Vorup-Jensen T, Kessler B, et al. (2006) Activation of the lectin pathway by natural IgM in a model of ischemia reperfusion injury. J Immunol 177: 4727-4734.

[36] Kim SJ, Gershov D, Ma X, Brot N, Elkon KB (2002) I-PLA2 Activation during Apoptosis Promotes the Exposure of Membrane Lysophosphatidylcholine Leading to Binding by Natural Immunoglobulin M Antibodies and Complement Activation. The Journal of Experimental Medicine 196 : 655-665.

[37] R. Langhorn and J.L. Willesen. Cardiac Troponins in Dogs and Cats. J Vet Intern Med 2016; 30:36-50.

[38] Sungwon Lee, Youngjoo Lee, Jiyeon Kim et al. Atorvastatin and rosuvastatin improve physiological parameters and alleviate immune dysfunction in metabolic disorders. Biochem Biophys Res Commun. 2016 Sep 23; 478 (3): 1242-7.

[39] Ametov AS, Kulidzhanian NK. Diabetes mellitus is an independent risk factor for cardiovascular disease. Ter Arkh. 2012; 84 (8): 91-4.

[40] Yutaka Nakashima, Andrew S. Plump, Elaine W. Raines et al. Arterioscler Thromb. 1994 Jan; 14 (1): 133-40.

[41] Yvonne Nitschke, Gabriele Weissen-Plenz, Robert Terkeltaub et al. Nppl promotes atherosclerosis in ApoE knockout mice. J. Cell. Mol. Med. Vol 15, No 11, 2011 pp. 2273-2283 ..

<110> Shenzhen Ruijian Life Science Research Institute Co., Ltd.

<120> A method for preventing and treating lipid kidney injury

<130> F17WO376TW

<160> 14

<170> PatentIn version 3.5

<210> 1

<211> 2376

<212> DNA

<213> Natural plasminogen (Glu-PLG, Glu-plasminogen) nucleic acid sequence without signal peptide

<400> 1

<210> 2

<211> 791

<212> PRT

<213> Amino acid sequence of natural plasminogen (Glu-PLG, Glu-plasminogen) without signal peptide

<400> 2

<210> 3

<211> 2433

<212> DNA

<213> Nucleic acid sequence of natural plasminogen (derived from swiss prot) containing signal peptide

<400> 3

<210> 4

<211> 810

<212> PRT

<213> Amino acid sequence of natural plasminogen (derived from swiss prot) containing signal peptide

<400> 4

<210> 5

<211> 2145

<212> DNA

<213> LYS77-PLG (Lys-plasminogen) nucleic acid sequence

<400> 5

<210> 6

<211> 714

<212> PRT

<213> LYS77-PLG (Lys-plasminogen) amino acid sequence

<400> 6

<210> 7

<211> 1245

<212> DNA

<213> delta-plg (delta-plasminogen) nucleic acid sequence

<400> 7

<210> 8

<211> 414

<212> PRT

<213> Delta-plg (delta-plasminogen) amino acid sequence

<400> 8

<210> 9

<211> 1104

<212> DNA

<213> Mini-plg (small plasminogen) nucleic acid sequence

<400> 9

<210> 10

<211> 367

<212> PRT

<213> Mini-plg (small plasminogen) amino acid sequence

<400> 10

<210> 11

<211> 750

<212> DNA

<213> Micro-plg (microplasminogen) nucleic acid sequence

<400> 11

<210> 12

<211> 249

<212> PRT

<213> Micro-plg (microplasminogen) amino acid sequence

<400> 12

<210> 13

<211> 684

<212> DNA

<213> Nucleic acid sequence of a serine protease (structural) domain

<400> 13

<210> 14

<211> 228

<212> PRT

<213> Amino acid sequence of serine protease (structural) domain

<400> 14

Claims (10)

    A method for preventing and / or treating lipid kidney injury and related conditions in a subject, comprising administering to the subject a prophylactic and / or therapeutically effective amount of plasminogen, wherein the subject is susceptible to fat metabolism disorders, Suffering from fat metabolism disorders or other diseases with lipid kidney damage.         The method of claim 1, wherein the lipid kidney injury is an endocrine disorder, a glucose metabolism disease, a liver disease, a kidney disease, a cardiovascular disease, an intestinal disease, a thyroid disease, a gallbladder or biliary disease, obesity, drinking, a drug Treatment initiates or accompanies lipid kidney damage.         The method of claim 2, wherein the lipid kidney injury is hyperlipidemia, hypertension, diabetes, chronic glomerulonephritis, chronic pyelonephritis, renal syndrome, renal insufficiency, kidney transplantation, uremia, hypothyroidism, Obstructive cholecystitis, obstructive cholangitis, drug or hormone therapy-induced or concomitant lipid kidney damage.         The method of any one of claims 1-3, wherein the kidney injury is caused by hyperlipidemia.         The method of claim 4, wherein the hyperlipidemia is type I, type IIa, type IIb, type III or type IV hyperlipidemia.         The method of claim 4, wherein the hyperlipidemia comprises one or more selected from the group consisting of hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, and low-high-density lipoproteinemia.         The method of any one of claims 1-6, wherein the plasminogen reduces renal fat deposition.         The method of any one of claims 1-7, wherein the plasminogen reduces renal fibrosis.         The method of claim 8, wherein said renal fibrosis is secondary to renal injury.         A method for preventing and / or treating diabetic lipid kidney injury and related conditions in a subject, comprising administering to the subject a prophylactic and / or therapeutically effective amount of plasminogen.